• Abrahamsson A, Krapivner S, Gustafsson U, Muhrbeck O, Eggertsen G, Johansson I, Persson I, Angelin B, Ingelman-Sundberg M, Bjorkhem I, Einarsson C, Hooft FM. Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration. Atherosclerosis 182: 37-45 (2005).

• Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, Yamada S, Makishima M. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J. Lipid Res. 46: 46-57 (2005). *

• Akerlund JE, Bjorkhem I, Angelin B, Liljeqvist L, Einarsson K. Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism. Gut 35: 1116-1120 (1994). *

• Aller MA, Arias JL, Prieto I, Losada M, Arias J. Bile duct ligation: step-by-step to cholangiocyte inflammatory tumorigenesis. Eur. J. Gastroenterol. Hepatol. Jul 28 [Epub ahead of print] (2009).

• Alnounou M, Munoz SJ. Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100 (2006). *

• Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, Onori P, Franchitto A, Coufal M, Frampton G, Alvaro D, Lee SP, Marzioni M, Benedetti A, DeMorrow S. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 68: 9184-9193 (2008). *

• Alvarez F. Treatments in chronic cholestasis in children. Ann. Nestle [Engl.] 66: 127-135 (2008).

• Alvarez L, Jara P, Sanchez-Sabate E, Hierro L, Larrauri J, Diaz MC, Camarena C, De La Vega A, Frauca E, Lopez-Collazo E, Lapunzina P. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet. 13: 2451-2460 (2004). *

• Amador-Noguez D, Dean A, Huang W, Setchell K, Moore D, Darlington G. Alterations in xenobiotic metabolism in the long-lived Little mice. Aging Cell 6: 453-470 (2007). *

• Angelin B. Telling the liver (not) to make bile acids: a new voice from the gut? Cell. Metab. 2: 209-210 (2005). *

• Angelin B, Eriksson M, Parini P, Rudling M. Bile acids and lipoproteins. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 31. June 18-19 (2004). *

• Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44 (2002).

• Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570 (1999). *

• Armendariz AD, Krauss RM. Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. Curr. Opin. Lipidol. 20: 106-111 (2009).

• Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol. Med. 9: 558-564 (2003). *

• Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).

• Auci DL, Reading CL, Frincke JM. 7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases. Autoimmun. Rev. 8: 369-372 (2009).

• Azad Khan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br. J. Clin. Pharmacol. 13: 523-528 (1982).

• Azer SA. A multimedia CD-ROM tool to improve student understanding of bile salts and bilirubin metabolism: evaluation of its use in a medical hybrid PBL course. Adv. Physiol. Educ. 29: 40-50 (2005). *

• Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Horl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M. Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int. 28: 948-958 (2008). *

• Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589 (1997). *

• Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Baranowski M. Biological role of liver X receptors. J. Physiol. Pharmacol. 59 Suppl. 7: 31-55 (2008). *

• Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol. 100: 2560-2568 (2005). *

• Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278: 32852-32860 (2003). *

• Barbier O, Trottier J, Kaeding J, Caron P, Verreault M. Lipid-activated transcription factors control bile acid glucuronidation. Mol. Cell. Biochem. 326: 3-8 (2009). *

• Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *

• Barth A, Braun J, Muller D. Influence of verapamil and cyclosporin A on bile acid metabolism and transport in rat liver slices. Exp. Toxicol. Pathol. 58: 31-37 (2006). *

• Barth A, Braun J, Muller D. Bile acid transport and metabolism in rat liver slices. Exp. Toxicol. Pathol. 57: 313-319 (2006).

• Batta AK, Salen G, Abroon J. Ursocholic acid, a hydrophilic bile acid, fails to improve liver function parameters in primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am. J. Gastroenterol. 92: 1035-1037 (1997).

• Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, Eskreis D, Katz S. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 10: 414-419 (1989).

• Batta AK, Salen G, Mirchandani R, Tint GS, Shefer S, Batta M, Abroon J, O'Brien CB, Senior JR. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 88: 691-700 (1993).

• Bayliss M, Somers G. Isolation and culture of human hepatocytes. Methods Mol. Med. 107: 249-268 (2004).

• Beath SV. Hepatic function and physiology in the newborn. Semin. Neonatol. 8: 337-346 (2003).

• Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem. Biophys. Res. Commun. 293: 145-149 (2002). *

• Bender S, Sauer H, Hoffmann D. Kinetics of bile acid metabolism in experimental blind loop syndrome. Gut 16: 927-931 (1975). *

• Berard AM, Dumon MF, Darmon M. Dietary fish oil up-regulates cholesterol 7alpha-hydroxylase mRNA in mouse liver leading to an increase in bile acid and cholesterol excretion. FEBS Lett. 559: 125-128 (2004). *

• Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43: 1078-1088 (2005). *

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *

• Berger A, Roberts MA, Hoff B. How dietary arachidonic- and docosahexaenoic- acid rich oils differentially affect the murine hepatic transcriptome. Lipids Health Dis. 5: 10 (2006). *

• Berr F, Pratschke E, Fischer S, Paumgartner G. Disorders of bile acid metabolism in cholesterol gallstone disease. J. Clin. Invest. 90: 859-868 (1992). *

• Bertok L. Bile acids in physico-chemical host defence. Pathophysiology 11: 139-145 (2004).

• Bertolami MC. Mechanisms of hepatotoxicity. Arq. Bras. Cardiol. 85 Suppl. 4: 25-27 (2005).

• Bertolotti M, Gabbi C, Anzivino C, Crestani M, Mitro N, Del Puppo M, Godio C, De Fabiani E, Macchioni D, Carulli L, Rossi A, Ricchi M, Loria P, Carulli N. Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur. J. Clin. Invest. 37: 501-508 (2007). *

• Bertolotti M, Gabbi C, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Del Puppo M, Ricchi M, Carulli L, Rossi A, Loria P, Carulli N. Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. Eur. J. Clin. Invest. 36: 170-175 (2006).

• Beuers U. Mechanisms of action of ursodeoxycholic acid in cholestasis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 49-50. October 15-16 (2003). *

• Beuers U, Fischer S, Spengler U, Paumgartner G. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man. J. Hepatol. 13: 97-103 (1991).

• Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK. Ligand-activated PXR interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha: functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279: 45139-45147 (2004). *

• Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J. Clin. Invest. 116: 2571-2579 (2006). *

• Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 49: 637-645 (2009). *

• Bishop-Bailey D. FXR as a novel therapeutic target for vascular disease. Drug News Perspect. 17: 499-504 (2004).

• Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. U.S.A. 101: 3668-3673 (2004). *

• Bisschop PH, Bandsma RH, Stellaard F, Ter Harmsel A, Meijer AJ, Sauerwein HP, Kuipers F, Romijn JA. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am. J. Clin. Nutr. 79: 570-576 (2004). *

• Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H. Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 37: 62-67 (2002). *

• Bjornsson E, Chapman RW. Sclerosing cholangitis. Curr. Opin. Gastroenterol. 19: 270-275 (2003).

• Blazovics A. Gallstone disease: free radical reactions and the ambivalent role of bilirubin in the pathomechanism of gallstone formation. Orv. Hetil. 148: 589-596 (2007).

• Bloks VW, Bakker-Van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia 47: 104-112 (2004). *

• Boberg KM, Lundin KE, Schrumpf E. Etiology and pathogenesis in primary sclerosing cholangitis. Scand. J. Gastroenterol. Suppl. 204: 47-58 (1994).

• Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat. Med. 14: 828-836 (2008). *

• Bochkis IM, Schug J, Rubins NE, Chopra AR, O'Malley BW, Kaestner KH. Foxa2-dependent hepatic gene regulatory networks depend on physiological state. Physiol. Genomics 38: 186-195 (2009). *

• Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *

• Bodin K. Role of CYP3A4 as a cholesterol and bile acid metabolizing enzyme. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 25. June 18-19 (2004). *

• Bodin K, Lindbom U, Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. Biochim. Biophys. Acta 1687: 84-93 (2005). *

• Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 278: 23529-23537 (2003). *

• Borst P, de Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453: 661-673 (2007). *

• Borst P, Oude Elferink RP. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71: 537-592 (2002). *

• Bouscarel B, Ceryak S, Robins SJ, Fromm H. Studies on the mechanism of the ursodeoxycholic acid-induced increase in hepatic low-density lipoprotein binding. Lipids 30: 607-617 (1995).

• Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J. Hepatol. 46: 365-371 (2007). *

• Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *

• Bremmelgaard A, Alme B. Analysis of plasma bile acid profiles in patients with liver diseases associated with cholestasis. Scand. J. Gastroenterol. 15: 593-600 (1980).

• Buijk SE, Gyssens IC, Mouton JW, Metselaar HJ, Groenland TH, Verbrugh HA, Bruining HA. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J. Antimicrob. Chemother. 54: 199-205 (2004). *

• Bunger M, van den Bosch HM, van der Meijde J, Kersten S, Hooiveld GJ, Muller M. Genome-wide analysis of PPARalpha activation in murine small intestine. Physiol. Genomics 30: 192-204 (2007). *

• Burkard I, von Eckardstein A, Rentsch KM. Differentiated quantification of human bile acids in serum by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 826: 147-159 (2005). *

• Burke KT, Horn PS, Tso P, Heubi JE, Woollett LA. Hepatic bile acid metabolism in the neonatal hamster: expansion of the bile acid pool parallels increased Cyp7a1 expression levels. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G144-G151 (2009).

• Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 3: e2267 (2008). *

• Buters JT, Zysset T, Reichen J. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. Biochem. Pharmacol. 46: 983-991 (1993).

• Cai SY, Boyer JL. FXR: a target for cholestatic syndromes? Expert Opin. Ther. Targets 10: 409-421 (2006).

• Cao WM, Murao K, Imachi H, Yu X, Dobashi H, Yoshida K, Muraoka T, Kotsuna N, Nagao S, Wong NC, Ishida T. Insulin like growth factor-I regulation of hepatic scavenger receptor class BI. Endocrinology 145: 5540-5547 (2004). *

• Capello A, Moons LM, Van de Winkel A, Siersema PD, van Dekken H, Kuipers EJ, Kusters JG. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am. J. Gastroenterol. 103: 1510-1516 (2008). *

• Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281: 11039-11049 (2006). *

• Carnahan VE, Redinbo MR. Structure and function of the human nuclear xenobiotic receptor PXR. Curr. Drug Metab. 6: 357-367 (2005).

• Carulli N, Ponz de Leon M, Zironi F, Iori R, Loria P. Bile acid feeding and hepatic sterol metabolism: effect of deoxycholic acid. Gastroenterology 79: 637-641 (1980).

• Carulli N, Ponz De Leon M, Zironi F, Pinetti A, Smerieri A, Iori R, Loria P. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short term feeding of chenodeoxycholic and ursodeoxycholic acid. J. Lipid Res. 21: 35-43 (1980). *

• Castro J, Amigo L, Miquel JF, Galman C, Crovari F, Raddatz A, Zanlungo S, Jalil R, Rudling M, Nervi F. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 45: 1261-1266 (2007). *

• Cha JY, Repa JJ. The liver X receptor and hepatic lipogenesis: the carbohydrate-response element binding protein is a target gene of LXR. J. Biol. Chem. 282: 743-751 (2007). *

• Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 50: 143-154 (2009). *

• Chang TK. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J. 11: 590-601 (2009). *

• Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).

• Chatterjee B, Echchgadda I, Song CS. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 400: 165-191 (2005).

• Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *

• Cheng JB, Motola DL, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Identification and characterization of CYP2R1, a microsomal vitamin D 25-hydroxylase. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 21. June 18-19 (2004). *

• Cheung C, Akiyama TE, Kudo G, Gonzalez FJ. Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem. Pharmacol. 66: 2011-2020 (2003). *

• Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23: 443-463 (2002). *

• Chiang JY. Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases. Curr. Opin. Investig. Drugs 6: 994-1001 (2005).

• Chiang JY. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin. Drug Metab. Toxicol. 5: 137-147 (2009).

• Chiang JY. Bile acids: regulation of synthesis. J. Lipid Res. Apr 3 [Epub ahead of print] (2009). *

• Chinese Human Liver Proteome Profiling Consortium. First insight into the human liver proteome from PROTEOME(SKY)-LIVER(Hu) 1.0, a publicly available database. J. Proteome Res. Sep 3 [Epub ahead of print] (2009). *

• Cho JY, Matsubara T, Kang DW, Ahn SH, Krausz KW, Idle JR, Luecke H, Gonzalez FJ. Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. J. Lipid Res. Nov 9 [Epub ahead of print] (2009). *

• Chow EC, Maeng HJ, Liu S, Khan AA, Groothuis GM, Pang KS. 1alpha,25-Dihydroxyvitamin D3 triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm. Drug Dispos. 30: 457-475 (2009). *

• Chow EK, Castrillo A, Shahangian A, Pei L, O'Connell RM, Modlin RL, Tontonoz P, Cheng G. A role for IRF3-dependent RXRalpha repression in hepatotoxicity associated with viral infections. J. Exp. Med. 203: 2589-2602 (2006). *

• Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. Sep 25 [Epub ahead of print] (2009). *

• Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125: 544-555 (2003). *

• Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25: 2020-2030 (2005). *

• Claudel T, Sturm E, Kuipers F, Staels B. The farnesoid X receptor: a novel drug target? Expert Opin. Investig. Drugs 13: 1135-1148 (2004).

• Claus SP, Tsang TM, Wang Y, Cloarec O, Skordi E, Martin FP, Rezzi S, Ross A, Kochhar S, Holmes E, Nicholson JK. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol. Syst. Biol. 4: 219 (2008). *

• Clayton PT. Inborn errors of bile acid metabolism. J. Inherit. Metab. Dis. 14: 478-496 (1991).

• Cohen BI, Hofmann AF, Mosbach EH, Stenger RJ, Rothschild MA, Hagey LR, Yoon YB. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology 91: 189-197 (1986).

• Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).

• Coleman JP, Kirby LC, Setchell KD, Hylemon PB, Pandak M, Heuman DM, Vlahcevic ZR. Metabolic fate and hepatocyte toxicity of reverse amide analogs of conjugated ursodeoxycholate in the rat. J. Steroid Biochem. Mol. Biol. 64: 91-101 (1998).

• Colombo C, Apostolo MG, Assaisso M, Roman B, Bottani P. Liver disease in cystic fibrosis. Neth. J. Med. 41: 119-122 (1992).

• Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 15: 677-684 (1992).

• Coltorti M, Bortolini M, Di Padova C. A review of the studies on the clinical use of S-adenosylmethionine (SAMe) for the symptomatic treatment of intrahepatic cholestasis. Methods Find. Exp. Clin. Pharmacol. 12: 69-78 (1990).

• Congiu M, Mashford ML, Slavin JL, Desmond PV. Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J. Gastroenterol. Hepatol. 24: 1038-1044 (2009). *

• Contestabile A. Benefits of caloric restriction on brain aging and related pathological states: understanding mechanisms to devise novel therapies. Curr. Med. Chem. 16: 350-361 (2009).

• Cook IT, Duniac-Dmuchowski Z, Kocarek TA, Runge-Morris M, Falany CN. 24-Hydroxycholesterol sulfation by human cytosolic sulfotransferases: formation of monosulfates and disulfates, molecular modeling, sulfatase sensitivity and inhibition of LXR activation. Drug Metab. Dispos. 37: 2069-2078 (2009). *

• Cornelius CE, Bruss ML. Hepatic bile pigment excretion and erythrocyte turnover in various species. Vet. Clin. Pathol. 9: 15-20 (1980).

• Cravetto C, Molino G, Hofmann AF, Belforte G, Bona B. Computer simulation of portal venous shunting and other isolated hepatobiliary defects of the enterohepatic circulation of bile acids using a physiological pharmacokinetic model. Hepatology 8: 866-878 (1988).

• Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, Favre CO, Rodriguez Garay EA, Mottino AD, Coleman R, Roma MG. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology 34: 329-339 (2001). *

• Crosignani A, Podda M, Bertolini E, Battezzati PM, Zuin M, Setchell KD. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 13: 1076-1083 (1991).

• Crotty B. Ulcerative colitis and xenobiotic metabolism. Lancet 343: 35-38 (1994).

• Crunkhorn S. Metabolic disease: dual benefit of bile acid receptor agonist. Nat. Rev. Drug Discov. 8: 848 (2009).

• Cuevas MJ, Almar M, Gonzalez-Gallego J. Effects of epomediol on ethinyloestradiol-induced changes in glutathione homeostasis in the rat. Pharmacol. Toxicol. 90: 121-126 (2002). *

• Cui J, Heard TS, Yu J, Lo JL, Huang L, Li Y, Schaeffer JM, Wright SD. The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate. J. Biol. Chem. 277: 25963-25969 (2002). *

• Cui NQ, Zhang SK, Cui YF, Li DH, Chen C, Wu XZ. Overexpression of sterol carrier protein-2 mRNA in patients with cholesterol gallstones. Hepatobiliary Pancreat Dis. Int. 4: 117-120 (2005). *

• Cuthbert JA. Wilson's disease: a new gene and an animal model for an old disease. J. Investig. Med. 43: 323-336 (1995).

• Dahlman-Wright K, Zhao C. LXR in cholesterol metabolism. J. Endocrinol. Oct 16 [Epub ahead of print] (2009). *

• Dastani Z, Engert JC, Genest J, Marcil M. Genetics of high-density lipoproteins. Curr. Opin. Cardiol. 21: 329-335 (2006).

• Davies NA, Wright G, Ytrebo LM, Stadlbauer V, Fuskevag OM, Zwingmann C, Davies DC, Habtesion A, Hodges SJ, Jalan R. L-Ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 50: 155-164 (2009). *

• Dawson PA, Rao A, Craddock AL, Haywood J. Analysis of the molecular mechanisms responsible for intestinal basolateral bile acid transport. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 43 (2006). *

• De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J. Biol. Chem. 278: 39124-39132 (2003). *

• De Fabiani E, Mitro N, Godio C, Gilardi F, Caruso D, Crestani M. Bile acid signaling to the nucleus: finding new connections in the transcriptional regulation of metabolic pathways. Biochimie 86: 771-778 (2004).

• Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc. Drug Rev. 25: 375-390 (2007).

• Denk GU, Cai SY, Chen WS, Lin A, Soroka CJ, Boyer JL. A comparison of gene expression in mouse liver and kidney in obstructive cholestasis utilizing high-density oligonucleotide microarray technology. World J. Gastroenterol. 12: 2536-2548 (2006). *

• Der G, Love T, Schreck J, Horn M. Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16 (2005). *

• Dietrich CG, Geier A, Wasmuth HE, Matern S, Gartung C, de Waart DR, Oude Elferink RP. Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen. Gut 53: 1850-1855 (2004). *

• Dixit M, Choudhuri G, Keshri LJ, Mittal B. Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease. J. Gastroenterol. Hepatol. 21: 847-849 (2006). *

• Doege H, Baillie RA, Ortegon AM, Tsang B, Wu Q, Punreddy S, Hirsch D, Watson N, Gimeno RE, Stahl A. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 130: 1245-1258 (2006). *

• Doherty MM, Poon K, Tsang C, Pang KS. Transport is not rate-limiting in morphine glucuronidation in the single pass perfused rat liver preparation. J. Pharmacol. Exp. Ther. 317: 890-900 (2006). *

• Dong B, Qatanani M, Moore DD. Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. Hepatology 50: 622-629 (2009).

• Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11: 1079-1092 (2003). *

• Duan RD. Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim. Biophys. Acta 1761: 281-291 (2006). *

• Dubrac S, Lear SR, Ananthanarayanan M, Balasubramaniyan N, Bollineni J, Shefer S, Hyogo H, Cohen DE, Blanche PJ, Krauss RM, Batta AK, Salen G, Suchy FJ, Maeda N, Erickson SK. Role of CYP27A in cholesterol and bile acid metabolism. J. Lipid Res. 46: 76-85 (2005). *

• Dueland S, Reichen J, Everson GT, Davis RA. Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem. J. 280: 373-377 (1991).

• Duez H, Veen JV, Duhem C, Pourcet B, Touvier T, Fontaine C, Derudas B, Bauge E, Havinga R, Bloks VW, Wolters H, van der Sluijs FH, Vennstrom B, Kuipers F, Staels B. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology 135: 689-698.e5 (2008). *

• Duran-Sandoval D, Cariou B, Fruchart JC, Staels B. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 87: 93-98 (2005).

• Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart JC, Kuipers F, Staels B. The farnesoid X receptor modulates hepatic carbohydrate metabolism during fasting/refeeding transition. J. Biol. Chem. 280: 29971-29979 (2005). *

• Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, Kuipers F, Staels B. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53: 890-898 (2004). *

• Echchgadda I, Song CS, Oh T, Ahmed M, De La Cruz IJ, Chatterjee B. The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase. Mol. Endocrinol. 21: 2099-2111 (2007). *

• Echchgadda I, Song CS, Roy AK, Chatterjee B. Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol. Pharmacol. 65: 720-729 (2004). *

• Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43: 2-12 (2002). *

• Eghdamian B, Ghose K. Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc.) 34: 943-956 (1998).

• Eipel C, Eisold M, Schuett H, Vollmar B. Inhibition of heme oxygenase-1 protects against tissue injury in carbon tetrachloride exposed livers. J. Surg. Res. 139: 113-120 (2007). *

• Elam MB, Cowan GS Jr, Rooney RJ, Hiler ML, Yellaturu CR, Deng X, Howell GE, Park EA, Gerling IC, Patel D, Corton JC, Cagen LM, Wilcox HG, Gandhi M, Bahr MH, Allan MC, Wodi LA, Cook GA, Hughes TA, Raghow R. Hepatic gene expression in morbidly obese women: implications for disease susceptibility. Obesity (Silver Spring) 17: 1563-1573 (2009). *

• Elias E, Mills CO. Coordinated defence and the liver. Clin. Med. 7: 180-184 (2007).

• Eliseo T, Ragona L, Catalano M, Assfalg M, Paci M, Zetta L, Molinari H, Cicero DO. Structural and dynamic determinants of ligand binding in the ternary complex of chicken liver bile acid binding protein with two bile salts revealed by NMR. Biochemistry 46: 12557-12567 (2007). *

• Ellis EC. Suppression of bile acid synthesis by thyroid hormone in primary human hepatocytes. World J. Gastroenterol. 12: 4640-4645 (2006). *

• Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433: 397-412 (2005). *

• Enjoji M, Yada R, Fujino T, Yoshimoto T, Yada M, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Nakamuta M. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol. Int. Jun 16 [Epub ahead of print] (2009). *

• Erichsen TJ, Aehlen A, Ehmer U, Kalthoff S, Manns MP, Strassburg CP. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids. J. Hepatol. Feb 4 [Epub ahead of print] (2010).

• Erickson JM, Mawson AR. Possible role of endogenous retinoid (vitamin A) toxicity in the pathophysiology of primary biliary cirrhosis. J. Theor. Biol. 206: 47-54 (2000). *

• Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, Bollineni JS, Shefer S, Hyogo H, Cohen DE, Shneider B, Sehayek E, Ananthanarayanan M, Balasubramaniyan N, Suchy FJ, Batta AK, Salen G. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44: 1001-1009 (2003). *

• Eusufzai S, Ericsson S, Cederlund T, Einarsson K, Angelin B. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. Gut 32: 1044-1048 (1991). *

• Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state kinetics of bile acids. J. Lipid Res. 29: 68-76 (1988). *

• Ewerth S. On the enterohepatic circulation of bile acids in man. Acta Chir. Scand. Suppl. 513: 1-38 (1982).

• Falany CN, Xie X, Wheeler JB, Wang J, Smith M, He D, Barnes S. Molecular cloning and expression of rat liver bile acid CoA ligase. J. Lipid Res. 43: 2062-2071 (2002). *

• Fang S, Tsang S, Jones R, Ponugoti B, Yoon H, Wu SY, Chiang CM, Willson TM, Kemper JK. The P300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP. J. Biol. Chem. 283: 35086-35095 (2008). *

• Fayard E, Schoonjans K, Auwerx J. Xol INXS: role of the liver X and the farnesol X receptors. Curr. Opin. Lipidol. 12: 113-120 (2001).

• Feuer G, Di Fonzo CJ. Intrahepatic cholestasis: a review of biochemical-pathological mechanisms. Drug Metabol. Drug Interact. 10: 1-161 (1992).

• Fickert P, Moustafa T, Fuchsbichler A, Claudel T, Halilbasic E, Kratky D, Zatloukal K, Denk H, Trauner M. Differential effects of ursodeoxycholic acid (UDCA) and sidechain-shortened norUDCA in the treatment of fatty liver and atherosclerosis. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 54 (2008). *

• Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481 (2006). *

• Figge A, Matern S, Lammert F. Molecular genetics of cholesterol cholelithiasis: identification of human and murine gallstone genes. Z. Gastroenterol. 40: 425-432 (2002).

• Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr. Pharm. Des. 15: 490-516 (2009).

• Fiorucci S, Baldelli F. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol. 25: 252-259 (2009).

• Fiorucci S, Mencarelli A, Distrutti E, Palladino G, Cipriani S. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem. Nov 24 [Epub ahead of print] (2009).

• Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J. Mol. Med. 80: 271-281 (2002). *

• Fletcher N, Wahlstrom D, Lundberg R, Nilsson CB, Nilsson KC, Stockling K, Hellmold H, Hakansson H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol. Appl. Pharmacol. 207: 1-24 (2005). *

• Fon Tacer K, Kuzman D, Seliskar M, Pompon D, Rozman D. TNF-alpha interferes with lipid homeostasis and activates acute and pro-atherogenic processes. Physiol. Genomics 31: 216-227 (2007). *

• Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65: 261-311 (2003). *

• Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).

• Frank C, Makkonen H, Dunlop TW, Matilainen M, Vaisanen S, Carlberg C. Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J. Mol. Biol. 346: 505-519 (2005). *

• Frederiksen SL, Chen W. D-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD004182 (2004). *

• Fuchs M. Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G551-G557 (2003). *

• Fujino T, Une M, Imanaka T, Inoue K, Nishimaki-Mogami T. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. J. Lipid Res. 45: 132-138 (2004). *

• Fujiwara K. Clinical examination of serum bile acids for the diagnosis of hepatobiliary diseases. Rinsho Byori 37: 1114-1121 (1989).

• Fukuchi J, Song C, Dai Q, Hiipakka RA, Liao S. 5beta-Cholane activators of the farnesol X receptor. J. Steroid Biochem. Mol. Biol. 94: 311-318 (2005).

• Fukumoto Y, Okita K, Kodama T, Noda K, Harada T, Mizuta M, Takemoto T. Studies of alpha-napthylisothiocyanate-induced hepatic disturbance. Hepatogastroenterology 27: 457-464 (1980).

• Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 12: 486-491 (1990).

• Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 129: 1445-1453 (2005). *

• Galman C, Ostlund-Lindqvist AM, Bjorquist A, Schreyer S, Svensson L, Angelin B, Rudling M. Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB J. 17: 265-267 (2003). *

• Gbaguidi GF, Agellon LB. The atypical interaction of peroxisome proliferator-activated receptor alpha with liver X receptor alpha antagonizes the stimulatory effect of their respective ligands on the murine cholesterol 7alpha-hydroxylase gene promoter. Biochim. Biophys. Acta 1583: 229-236 (2002). *

• Geier A, Dietrich CG, Grote T, Beuers U, Prufer T, Fraunberger P, Matern S, Gartung C, Gerbes AL, Bilzer M. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J. Hepatol. 43: 1021-1030 (2005). *

• Gems D. Long-lived dwarf mice: are bile acids a longevity signal? Aging Cell 6: 421-423 (2007). *

• Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl. Recept. 2: 4 (2004). *

• Gimeno RE. Fatty acid transport proteins. Curr. Opin. Lipidol. 18: 271-276 (2007).

• Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, Hum DW, Fruchart JC, Staels B. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol. Endocrinol. 22: 2433-2447 (2008). *

• Gnerre C, Blattler S, Kaufmann MR, Looser R, Meyer UA. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14: 635-645 (2004).

• Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL, Leitersdorf E, Mangelsdorf DJ, Kliewer SA, Repa JJ. Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 100: 223-228 (2003). *

• Goodwin B, Kliewer SA. Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G926-G931 (2002). *

• Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Contribution of canalicular glutathione efflux to bile formation. From cholestasis associated alterations to pharmacological intervention to modify bile flow. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 153-161 (2005).

• Green RM, Hoda F, Ward KL. Molecular cloning and characterization of the murine bile salt export pump. Gene 241: 117-123 (2000). *

• Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch. Dis. Child. 69: 141-143 (1993).

• Groen AK. The emerging role of bile acids as integrators of intermediary metabolism. J. Hepatol. 45: 337-338 (2006). *

• Groneberg DA, Grosse-Siestrup C, Fischer A. In vitro models to study hepatotoxicity. Toxicol. Pathol. 30: 394-399 (2002). *

• Gross JB Jr, Ludwig J, Wiesner RH, McCall JT, LaRusso NF. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 89: 272-278 (1985).

• Gruy-Kapral C, Little KH, Fordtran JS, Meziere TL, Hagey LR, Hofmann AF. Conjugated bile acid replacement therapy for short-bowel syndrome. Gastroenterology 116: 15-21 (1999). *

• Guariento M, Raimondo D, Assfalg M, Zanzoni S, Pesente P, Ragona L, Tramontano A, Molinari H. Identification and functional characterization of the bile acid transport proteins in non-mammalian ileum and mammalian liver. Proteins 70: 462-472 (2008).

• Gueguen Y, Souidi M, Baudelin C, Dudoignon N, Grison S, Dublineau I, Marquette C, Voisin P, Gourmelon P, Aigueperse J. Short-term hepatic effects of depleted uranium on xenobiotic and bile acid metabolizing cytochrome P450 enzymes in the rat. Arch. Toxicol. 80: 187-195 (2006). *

• Guengerich FP. Cytochromes P450, drugs, and diseases. Mol. Intervent. 3: 194-204 (2003). *

• Guitaoui M, Parquet M, Aubert C, Montet AM, Montet JC. Conjugation with taurine prevents side-chain desaturation of ursodeoxycholic and beta-muricholic acids in bile fistula rats. Fundam. Clin. Pharmacol. 18: 457-464 (2004). *

• Guldutuna S, Leuschner M, Wunderlich N, Nickel A, Bhatti S, Hubner K, Leuschner U. Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function. Eur. J. Clin. Pharmacol. 45: 221-225 (1993).

• Gunsar C, Melek M, Karaca I, Sencan A, Mir E, Ortac R, Canan O. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology 49: 497-500 (2002).

• Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, Sinal CJ. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278: 45062-45071 (2003). *

• Gustafsson J, Alvelius G, Bjorkhem I, Nemeth A. Bile acid metabolism in extrahepatic biliary atresia: lithocholic acid in stored dried blood collected at neonatal screening. Ups. J. Med. Sci. 111: 131-136 (2006). *

• Hagenauer B, Maier-Salamon A, Thalhammer T, Zollner P, Senderowicz A, Jager W. Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. Oncol. Rep. 11: 1069-1075 (2004).

• Halpern MD, Dvorak B. Does abnormal bile acid metabolism contribute to NEC? Semin. Perinatol. 32: 114-121 (2008). *

• Han KC, Kim JH, Kim KH, Kim EE, Seo JH, Yang EG. Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay. Anal. Biochem. Nov 11 [Epub ahead of print] (2009). *

• Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55: 649-673 (2003). *

• Handschin C, Podvinec M, Amherd R, Looser R, Ourlin JC, Meyer UA. Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J. Biol. Chem. 277: 29561-29567 (2002). *

• Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional farnesoid X-receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46: 2595-2604 (2005). *

• Hardison WG, Grundy SM. Effect of bile acid conjugation pattern on bile acid metabolism in normal humans. Gastroenterology 84: 617-620 (1983).

• Haussinger D, Schliess F. Glutamine metabolism and signaling in the liver. Front. Biosci. 12: 371-391 (2007).

• He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, Pitt B, Xie W, Li S. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 98: 192-199 (2006). *

• Hegele RA, Robinson JF. ABC transporters and sterol absorption. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 31-37 (2005).

• Hempfling W, Dilger K, Beuers U. Ursodeoxycholic acid - adverse effects and drug interactions. Aliment. Pharmacol. Ther. 18: 963-972 (2003). *

• Henderson CJ, Wolf CR. Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology. Mol. Intervent. 3: 331-343 (2003). *

• Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, Oosterveer MH, Reijngoud DJ, Muller M, Stellaard F, Groen AK, Kuipers F. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptoralpha-controlled metabolic pathways in mice. Hepatology Oct 23 [Epub ahead of print] (2009). *

• Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. Semin. Liver Dis. 27: 282-294 (2007).

• Higashiyama H, Kinoshita M, Asano S. Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. Acta Histochem. 110: 86-93 (2008).

• Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Curr. Mol. Med. 3: 483-490 (2003).

• Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279: 45685-45692 (2004). *

• Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130: 1793-1806 (2006). *

• Hobbs HH, Cohen JC. ABCG5 and ABCG8 play major role in defense against sterol accumulation. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 55. June 18-19 (2004). *

• Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur. J. Clin. Pharmacol. 28: 475-477 (1985).

• Hoffmann RM, Schwarz G, Pohl C, Ziegenhagen DJ, Kruis W. Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility. Dtsch. Med. Wochenschr. 130: 1938-1943 (2005).

• Hofmann AF. Bile acids as drugs: principles, mechanisms of action and formulations. Ital. J. Gastroenterol. 27: 106-113 (1995).

• Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14: 24-29 (1999). *

• Hofmann AF. Progress in idiopathic bile acid malabsorption. Gut 43: 738-739 (1998). *

• Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159: 2647-2658 (1999). *

• Hofmann AF. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 49: 1403-1418 (2009). *

• Hofmann AF, Cravetto C, Molino G, Belforte G, Bona B. Simulation of the metabolism and enterohepatic circulation of endogenous deoxycholic acid in humans using a physiologic pharmacokinetic model for bile acid metabolism. Gastroenterology 93: 693-709 (1987).

• Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65: 2461-2483 (2008). *

• Hofmann AF, Loening-Baucke V, Lavine JE, Hagey LR, Steinbach JH, Packard CA, Griffin TL, Chatfield DA. Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J. Pediatr. Gastroenterol. Nutr. 47: 598-606 (2008). *

• Hofmann AF, Molino G, Milanese M, Belforte G. Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile acids in man. Cholic acid in healthy man. J. Clin. Invest. 71: 1003-1022 (1983). *

• Houdijk AP, Oosterling SJ, Siroen MP, de Jong S, Richir M, Rijssenbeek AL, Teerlink T, van Leeuwen PA. Hypertaurinemia in bile duct-ligated rats after surgery: the effect of gut endotoxin restriction on organ fluxes and oxidative status. JPEN J. Parenter. Enteral Nutr. 30: 186-193 (2006). *

• Houten S, Auwerx J. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann. Med. 36: 482-491 (2004).

• Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 25: 1419-1425 (2006). *

• Howard PJ, Murphy GM. Bile acid stress in the mother and baby unit. Eur. J. Gastroenterol. Hepatol. 15: 317-321 (2003).

• Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, Li S, Gao H, Ryan TP, Michael MD, Michael LF. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J. Biol. Chem. 281: 39831-39838 (2006). *

• Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR, de Pedro N, Royo I, Blevins RA, Pelaez F, Wright SD, Cui J. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 278: 51085-51090 (2003). *

• Huang X, Yang C, Jin C, Luo Y, Wang F, McKeehan WL. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol. Carcinog. 48: 553-562 (2009). *

• Hubbard B, Doege H, Punreddy S, Wu H, Huang X, Kaushik VK, Mozell RL, Byrnes JJ, Stricker-Krongrad A, Chou CJ, Tartaglia LA, Lodish HF, Stahl A, Gimeno RE. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130: 1259-1269 (2006). *

• Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, Hollis GF, Young PR, Mukherjee R, Burn TC. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290: 35-43 (2002). *

• Hulzebos CV, Bijleveld CM, Stellaard F, Kuipers F, Fidler V, Slooff MJ, Peeters PM, Sauer PJ, Verkade HJ. Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation. Liver Transpl. 10: 872-880 (2004). *

• Hunt MC, Yang YZ, Eggertsen G, Carneheim CM, Gafvels M, Einarsson C, Alexson SE. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J. Biol. Chem. 275: 28947-28953 (2000). *

• Hunter RJ, Patel VB, Baker AJ, Preedy VR. Liver dysfunction induced by bile duct ligation and galactosamine injection alters cardiac protein synthesis. Metabolism 53: 964-968 (2004). *

• Hylemon PB, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, Pandak WM, Dent P. Conjugated bile acids promote activation of the ERK 1/2 and AKT pathways via a pertussis toxin-sensitive GI-dependent mechanism in primary rodent and human hepatocytes. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 24 (2006). *

• Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J. Lipid Res. 50: 1509-1520 (2009). *

• Hyogo H, Tazuma S, Cohen DE. Cholesterol gallstones. Curr. Opin. Gastroenterol. 18: 366-371 (2002).

• Iguchi Y, Kihira K, Nishimaki-Mogami T, Une M. Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist. Steroids 75: 95-100 (2010).

• Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bouscarel B, Tanaka N. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A(2) expression in HepG2 cells. Hepatology 41: 896-905 (2005). *

• Inoue Y, Yu AM, Inoue J, Gonzalez FJ. Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation. J. Biol. Chem. 279: 2480-2489 (2004). *

• Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, Xiang CC, Brownstein MJ, Eggertsen G, Bjorkhem I, Gonzalez FJ. Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J. Lipid Res. 47: 215-227 (2006). *

• Invernizzi P, Setchell KD, Crosignani A, Battezzati PM, Larghi A, O'Connell NC, Podda M. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 29: 320-327 (1999). *

• Ishizaki K, Imada T, Tsurufuji M. Hepatoprotective bile acid 'ursodeoxycholic acid (UDCA)' property and difference as bile acids. Hepatol. Res. 33: 174-177 (2005).

• Izzat NN, Overturf M, Weisbrodt NW, Loose DS. Bile acid transport in hypercholesterolemic resistant rabbits. J. Physiol. Pharmacol. 60: 79-84 (2009). *

• Jacquemin E. Progressive familial intrahepatic cholestasis. J. Gastroenterol. Hepatol. 14: 594-599 (1999).

• Jacquemin E, Dumont M, Bernard O, Erlinger S, Hadchouel M. Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease). Eur. J. Pediatr. 153: 424-428 (1994).

• Jahnel J, Fickert P, Langner C, Hogenauer C, Silbert D, Gumhold J, Fuchsbichler A, Trauner M. Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. Liver Int. 29: 1316-1325 (2009). *

• Jansen GR. Effect of delta(22)-5beta-taurocholenic acid on hepatic cholesterol and fatty acid in gold thioglucose obese mice fed low- or high-fat diets. J. Nutr. Biochem. 10: 638-643 (1999).

• Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23: 315-322 (2003). *

• Javitt NB. Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J. 4: 161-168 (1990). *

• Javitt NB. 26-Hydroxycholesterol: synthesis, metabolism, and biologic activities. J. Lipid Res. 31: 1527-1533 (1990). *

• Javitt NB. Diagnostic value of serum bile acids. Clin. Gastroenterol. 6: 219-226 (1977).

• Javitt NB. Cholesterol, hydroxycholesterols, and bile acids. Biochem. Biophys. Res. Commun. 292: 1147-1153 (2002). *

• Javitt NB, Budai K. Cholesterol and bile acid synthesis in Hep G2 cells. Metabolic effects of 26- and 7 alpha-hydroxycholesterol. Biochem. J. 262: 989-992 (1989). *

• Javitt NB, Kok E, Carubbi F, Blizzard T, Gut M, Byon CY. Bile acid synthesis. Metabolism of 3 beta-hydroxy-5-cholenoic acid to chenodeoxycholic acid. J. Biol. Chem. 261: 12486-12489 (1986). *

• Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M, Sutherland E, Arend L, Levi M. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56: 2485-2493 (2007). *

• Jiang W, Miyamoto T, Kakizawa T, Nishio SI, Oiwa A, Takeda T, Suzuki S, Hashizume K. Inhibition of LXRalpha signaling by vitamin D receptor: possible role of VDR in bile acid synthesis. Biochem. Biophys. Res. Commun. 351: 176-184 (2006). *

• Jiang ZY, Parini P, Eggertsen G, Davis MA, Hu H, Suo GJ, Zhang SD, Rudel LL, Han TQ, Einarsson C. Increased expression of LXRalpha , ABCG5, ABCG8 and SRBI in the liver from normolipidemic nonobese Chinese gallstone patients. J. Lipid Res. 49: 464-472 (2008). *

• Jones EA, Bergasa NV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur. J. Gastroenterol. Hepatol. 11: 623-631 (1999).

• Jonkers IJ, Smelt AH, Princen HM, Kuipers F, Romijn JA, Boverhof R, Masclee AA, Stellaard F. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J. Nutr. 136: 987-991 (2006). *

• Joplin R, Lindsay JG, Hubscher SG, Johnson GD, Shaw JC, Strain AJ, Neuberger JM. Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: an immunohistochemical study. Hepatology 14: 442-447 (1991).

• Jourdan M, Vaubourdolle M, Cynober L, Aussel C. Effect of aging on liver functions-an experimental study in a perfused rat liver model. Exp. Gerontol. 39: 1341-1346 (2004).

• Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 13: 155-164 (2002).

• Jump DB. Dietary polyunsaturated fatty acid regulation of hepatic gene transcription. Scand. J. Nutr. 46: 59-67 (2002). *

• Jung D, Elferink MG, Stellaard F, Groothuis GM. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int. 27: 137-144 (2007). *

• Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 277: 30559-30566 (2002). *

• Juppner H, Rittinghaus EF, Ahlgrimm M, Burdelski M, Dralle H. C-terminal PTH (70-84) after biliary ligation in rats: implications for the diagnostic importance in hepatobiliary disease. Biochem. Biophys. Res. Commun. 139: 633-636 (1986).

• Kaeding J, Bouchaert E, Belanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Belanger A, Barbier O. Activators of the farnesoid X-receptor negatively regulate androgen glucuronidation in human prostate cancer LNCaP cells. Biochem. J. 410: 245-253 (2008). *

• Kahn E. Biliary atresia revisited. Pediatr. Dev. Pathol. 7: 109-124 (2004).

• Kakizaki S, Takizawa D, Tojima H, Yamazaki Y, Mori M. Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease. Curr. Drug Targets Nov 1 [Epub ahead of print] (2009).

• Kakizaki S, Takizawa D, Tojima H, Yamazaki Y, Mori M. Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease. Curr. Drug Targets 10: 1184-1193 (2009).

• Kalaany NY, Mangelsdorf DJ. LXRs and FXR: the Yin and Yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68: 159-191 (2006). *

• Kamath AV, Chong S, Chang M, Marathe PH. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother. Pharmacol. 55: 110-116 (2005). *

• Kamisako T, Ogawa H. Effect of obstructive jaundice on the regulation of hepatic cholesterol metabolism in the rat. Disappearance of abcg5 and abcg8 mRNA after bile duct ligation. Hepatol. Res. 25: 99-104 (2003).

• Kamisako T, Ogawa H. Alteration of the expression of adenosine triphosphate-binding cassette transporters associated with bile acid and cholesterol transport in the rat liver and intestine during cholestasis. J. Gastroenterol. Hepatol. 20: 1429-1434 (2005). *

• Kamisako T, Ogawa H, Yamamoto K. Effect of cholesterol, cholic acid and cholestyramine administration on the intestinal mRNA expressions related to cholesterol and bile acid metabolism in the rat. J. Gastroenterol. Hepatol. 22: 1832-1837 (2007). *

• Kanayama T, Arito M, So K, Hachimura S, Inoue J, Sato R. Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities. J. Biol. Chem. 282: 10290-10298 (2007). *

• Kannenberg F, Ellinghaus P, Assmann G, Seedorf U. Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice. J. Biol. Chem. 274: 35455-35460 (1999). *

• Kaplan MM. Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am. J. Gastroenterol. 99: 2147-2149 (2004). *

• Karlsen TH, Boberg KM, Schrumpf E. Role of polymorphisms in genes involved in bile acid detoxification pathways in primary sclerosing cholangitis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 87 (2006). *

• Keitel V, Kubitz R, Haussinger D. Endocrine and paracrine role of bile acids. World J. Gastroenterol. 14: 5620-5629 (2008). *

• Keizman D, Goldiner I, Leikin-Frenkel A, Konikoff FM. Innovations in the medical treatment of gallstones and fatty liver: FABACs (fatty acid bile acid conjugates). Harefuah. 147: 344-349, 373, 372 (2008).

• Kemper JK, Kim H, Miao J, Bhalla S, Bae Y. Role of an mSin3A-Swi/Snf chromatin remodeling complex in the feedback repression of bile acid biosynthesis by SHP. Mol. Cell. Biol. 24: 7707-7719 (2004). *

• Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, Kanamaluru D, Tsang S, Wu SY, Chiang CM, Veenstra TD. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell. Metab. 10: 392-404 (2009).

• Keppler D, Konig J, Buchler M. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv. Enzyme Regul. 37: 321-333 (1997). *

• Kershenobich D, Antonio Alanis J, Fe Bornstein M, Perez Herrera M, Alvarado Ramos E, Irene Suarez G. Endotoxins and liver. Rev. Gastroenterol. Mex. 43: 49-57 (1978).

• Kesaniemi YA, Miettinen TA, Salaspuro MP. Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes. Gut 22: 579-584 (1981). *

• Khan SA, Jane Cox I, Thillainayagam AV, Bansi DS, Thomas HC, Taylor-Robinson SD. Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. Eur. J. Gastroenterol. Hepatol. 17: 733-738 (2005).

• Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196 (2004). *

• Kida T, Murata T, Hori M, Ozaki H. Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 296: H195-H201 (2009). *

• Kim MS, Shigenaga J, Moser A, Grunfeld C, Feingold KR. Suppression of DHEA sulfotransferase (Sult2A1) during the acute phase response. Am. J. Physiol. Endocrinol. Metab. 287: E731-E738 (2004). *

• Kim MS, Sweeney 1 TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, Feingold KR. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism 56: 267-279 (2007). *

• Kirkpatrick RB, Killenberg PG. Effects of ethinylestradiol on enzymes catalyzing bile acid conjugation and sulfation. J. Lipid Res. 21: 895-901 (1980). *

• Kirkpatrick RB, Kraft BG. Effect of streptozotocin-induced diabetes on bile acid sulfation in male rat liver. Am. J. Physiol. 247: G226-G230 (1984). *

• Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, Osaki Y, Tomono N, Hachiya T, Shimizu T. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am. J. Gastroenterol. 97: 1849-1851 (2002). *

• Kiyosawa N, Ito K, Niino N, Sakuma K, Kanbori M, Yamoto T, Manabe S, Matsunuma N. Effect of serum cholesterol on the mRNA content of amyloid precursor protein in rat livers. Toxicol. Lett. 150: 157-166 (2004). *

• Klaassen CD, Lu H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci. 101: 186-196 (2008). *

• Klein A, Amigo L, Retamal MJ, Morales MG, Miquel JF, Rigotti A, Zanlungo S. NPC2 is expressed in human and murine liver and secreted into bile: potential implications for body cholesterol homeostasis. Hepatology 43: 126-133 (2005). *

• Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23: 687-702 (2002). *

• Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774 (1992). *

• Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J. Lipid Res. 43: 359-364 (2002). *

• Kok T, Wolters H, Bloks VW, Havinga R, Jansen PL, Staels B, Kuipers F. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 124: 160-171 (2003). *

• Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129: 894-901 (2005). *

• Konikoff FM, Leikin-Frenkel A, Goldiner I, Michowitz M, Brezowski E, Harats D, Gilat T. Biliary and systemic effects of fatty acid bile acid conjugates. Eur. J. Gastroenterol. Hepatol. 15: 649-655 (2003).

• Koopen NR, Wolters H, Havinga R, Vonk RJ, Jansen PL, Muller M, Kuipers F. Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat. Hepatology 27: 537-545 (1998). *

• Koopman BJ, Wolthers BG, van der Molen JC, Nagel GT, Kruizinga W. Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid. Biochim. Biophys. Acta 917: 238-246 (1987).

• Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Kubik R, Hanson J, Urda E, Mutlib AE. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90: 451-459 (2006). *

• Kowdley KV. Lipids and lipid-activated vitamins in chronic cholestatic diseases. Clin. Liver Dis. 2: 373-389, x (1998).

• Krahenbuhl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology 20: 1595-1601 (1994).

• Krahenbuhl S, Krahenbuhl-Glauser S, Stucki J, Gehr P, Reichen J. Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte. Hepatology 15: 1167-1172 (1992).

• Kramer W, Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr. Med. Chem. 13: 997-1016 (2006).

• Krasowski MD, Yasuda K, Hagey LR, Schuetz EG. Evolution of the pregnane X receptor: adaptation to cross-species differences in biliary bile salts. Mol. Endocrinol. 19: 1720-1739 (2005). *

• Kreeft AJ, Moen CJ, Porter G, Kasanmoentalib S, Sverdlov R, van Gorp PJ, Havekes LM, Frants RR, Hofker MH. Genomic analysis of the response of mouse models to high-fat feeding shows a major role of nuclear receptors in the simultaneous regulation of lipid and inflammatory genes. Atherosclerosis 182: 249-257 (2005).

• Kretschmer NW, Boor PJ, el Azhary RA, Ahmed AE, Reynolds ES. Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity. III. Ultrastructural characterization of bile duct injury. Cancer Chemother. Pharmacol. 19: 109-117 (1987).

• Kretschmer XC, Baldwin WS. CAR and PXR: xenosensors of endocrine disrupters? Chem. Biol. Interact. 155: 111-128 (2005). *

• Krisans SK, Thompson SL, Pena LA, Kok E, Javitt NB. Bile acid synthesis in rat liver peroxisomes: metabolism of 26-hydroxycholesterol to 3 beta-hydroxy-5-cholenoic acid. J. Lipid Res. 26: 1324-1332 (1985). *

• Krishnamurthy K, Wang G, Rokhfeld D, Bieberich E. Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide. Breast Cancer Res. 10: R106 (2008). *

• Kubitz R, Keitel V, Burdelski M, Haussinger D. Regulation of hepatobiliary transporters in chronic cholestasis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 33-35 (2006). *

• Kudo A, Kashiwagi S, Kajimura M, Yoshimura Y, Uchida K, Arii S, Suematsu M. Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver. Hepatology 39: 1099-1109 (2004). *

• Kuipers F, Claudel T, Sturm E, Staels B. The farnesoid X receptor (FXR) as modulator of bile acid metabolism. Rev. Endocr. Metab. Disord. 5: 319-326 (2004). *

• Kuipers F, Stroeve JH, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr. Opin. Lipidol. 18: 289-297 (2007).

• Kuisma J, Nuutinen H, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am. J. Gastroenterol. 96: 3110-3116 (2001). *

• Kullak-Ublick GA. Regulation of hepatic and intestinal bile acid transport by FXR controlled signaling pathways. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 51-52 (2006). *

• Kullak-Ublick GA, Beuers U, Paumgartner G. Hepatobiliary transport. J. Hepatol. 32: S3-S18 (2000).

• Kumagai M, Kimura A, Takei H, Kurosawa T, Aoki K, Inokuchi T, Matsuishi T. Perinatal bile acid metabolism: bile acid analysis of meconium of preterm and full-term infants. J. Gastroenterol. 42: 904-910 (2007). *

• Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M. Tissue-specific expression of beta KLOTHO and fibroblast growth factor receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282: 26687-26695 (2007). *

• Kuver R, Savard CE, Lee SK, Haigh WG, Lee SP. Murine gallbladder epithelial cells can differentiate into hepatocyte-like cells in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G944-G955 (2007). *

• Lacaille F. Bile acids and their therapeutic use in children. Arch. Pediatr. 2: 1200-1208 (1995).

• Lam NV, Chen W, Suruga K, Nishimura N, Goda T, Yokogoshi H. Enhancing effect of taurine on CYP7A1 mRNA expression in Hep G2 cells. Amino Acids 30: 43-48 (2006). *

• Lambert C, Spire C, Claude N, Guillouzo A. Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol. Appl. Pharmacol. 234: 345-360 (2009). *

• Lambou-Gianoukos S, Heller SJ. Lithogenesis and bile metabolism. Surg. Clin. North Am. 88: 1175-1194 (2008).

• Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).

• Landrier JF, Malezet-Desmoulins C, Reboul E, Marie Lorec A, Josephe Amiot M, Borel P. Comparison of different vehicles to study the effect of tocopherols on gene expression in intestinal cells. Free Radic. Res. 42: 523-530 (2008).

• Lazaridis KN, Lindor KD. Primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 2: 473-480 (1999).

• Le Martelot G, Claudel T, Gatfield D, Schaad O, Kornmann B, Sasso GL, Moschetta A, Schibler U. REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis. PLoS Biol. 7: e1000181 (2009). *

• Leclerc D, Rozen R. Molecular genetics of MTHFR: polymorphisms are not all benign. Med. Sci. (Paris) 23: 297-302 (2007).

• Lee C, Martin KO, Javitt NB. Bile acid synthesis: 7 alpha-hydroxylation of intermediates in the sterol 27-hydroxylase metabolic pathway. J. Lipid Res. 37: 1356-1362 (1996). *

• Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31: 572-580 (2006). *

• Lee H, Hubbert ML, Osborne TF, Woodford K, Zerangue N, Edwards PA. Regulation of the sodium/sulfate co-transporter by farnesoid X receptor alpha. J. Biol. Chem. 282: 21653-21661 (2007). *

• Lee JY, Jung da W, Park HA, Kim SJ, Chung JH, Moon CK, Kim YC. Effect of taurine on biliary excretion and metabolism of acetaminophen in male hamsters. Biol. Pharm. Bull. 27: 1792-1796 (2004). *

• Lee YK, Moore DD. Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner. J. Biol. Chem. 277: 2463-2467 (2002). *

• Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89: 147-191 (2009). *

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, Rosenberg R, Bonen H, Litvak A, Bernheim J, Konikoff FM, Gilat T. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur. J. Gastroenterol. Hepatol. 20: 1205-1213 (2008).

• Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H, Happ J, Leuschner U. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117: 918-925 (1999). *

• Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498 (2003).

• Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).

• Levy E, Brunet S, Alvarez F, Seidman E, Bouchard G, Escobar E, Martin S. Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease. Life Sci. 80: 1472-1483 (2007). *

• Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr. Opin. Cardiol. 21: 345-352 (2006).

• Lewis S, Cochrane S. Alteration of sulfate and hydrogen metabolism in the human colon by changing intestinal transit rate. Am. J. Gastroenterol. 102: 624-633 (2007). *

• Li J, Pircher PC, Schulman IG, Westin SK. Regulation of complement C3 expression by the bile acid receptor FXR. J. Biol. Chem. 280: 7427-7434 (2005). *

• Li N, Palandra J, Nemirovskiy OV, Lai Y. LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across apecies. Anal. Chem. Feb 11 [Epub ahead of print] (2009). *

• Li S, Zhang ZW, Guan YF. On the bile acid receptor FXR. Sheng Li Ke Xue Jin Zhan 34: 314-318 (2003).

• Li T, Chanda D, Zhang Y, Choi HS, Chiang JY. Glucose stimulates cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription in human hepatocytes. J. Lipid Res. Oct 28 [Epub ahead of print] (2009). *

• Li T, Chen W, Chiang JY. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J. Lipid Res. 48: 373-384 (2007). *

• Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G74-G84 (2005). *

• Li T, Chiang JY. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res. 2009: 501739 (2009). *

• Li Y, Mezei O, Shay NF. Human and murine hepatic sterol-12-alpha-hydroxylase and other xenobiotic metabolism mRNA are upregulated by soy isoflavones. J. Nutr. 137: 1705-1712 (2007). *

• Li Y, Ross-Viola JS, Shay NF, Moore DD, Ricketts ML. Human CYP3A4 and murine Cyp3A11 are regulated by equol and genistein via the pregnane X receptor in a species-specific manner. J. Nutr. 139: 898-904 (2009).

• Li Z, White P, Tuteja G, Rubins N, Sackett S, Kaestner KH. Foxa1 and Foxa2 regulate bile duct development in mice. J. Clin. Invest. 119: 1537-1545 (2009). *

• Li-Hawkins J, Gafvels M, Olin M, Lund EG, Andersson U, Schuster G, Bjorkhem I, Russell DW, Eggertsen G. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J. Clin. Invest. 110: 1191-1200 (2002). *

• Li-Hawkins J, Lund EG, Bronson AD, Russell DW. Expression cloning of an oxysterol 7alpha-hydroxylase selective for 24-hydroxycholesterol. J. Biol. Chem. 275: 16543-16549 (2000). *

• Li-Hawkins J, Lund EG, Turley SD, Russell DW. Disruption of the oxysterol 7alpha-hydroxylase gene in mice. J. Biol. Chem. 275: 16536-16542 (2000). *

• Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem. 276: 49066-49076 (2001). *

• Liddle C, Goodwin B. Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Semin. Liver Dis. 22: 115-122 (2002).

• Lillienau J, Crombie DL, Munoz J, Longmire-Cook SJ, Hagey LR, Hofmann AF. Negative feedback regulation of the ileal bile acid transport system in rodents. Gastroenterology 104: 38-46 (1993).

• Lin Y, Dueker SR, Follett JR, Fadel JG, Arjomand A, Schneider PD, Miller JW, Green R, Buchholz BA, Vogel JS, Phair RD, Clifford AJ. Quantitation of in vivo human folate metabolism. Am. J. Clin. Nutr. 80: 680-691 (2004). *

• Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 27: 166-174 (1998). *

• Ling V, Lam P, Forrest D, Liu L, Wang R. Bile acid transport in Spgp (BSEP) knockout mice. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 37. June 18-19 (2004). *

• Lirussi F, Vaja S, Murphy GM, Dowling RH. Cholestasis of total parenteral nutrition: bile acid and bile lipid metabolism in parenterally nourished rats. Gastroenterology 96: 493-502 (1989).

• Liscovitch M, Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 1-7 (2002). *

• Liu Y, Havinga R, van der Leij FR, Boverhof R, Sauer PJ, Kuipers F, Stellaard F. Dexamethasone exposure of neonatal rats modulates biliary lipid secretion and hepatic expression of genes controlling bile acid metabolism in adulthood without interfering with primary bile acid kinetics. Pediatr. Res. 63: 375-381 (2008). *

• Los EL, Wolters H, Stellaard F, Kuipers F, Verkade HJ, Rings EH. Intestinal capacity to digest and absorb carbohydrates is maintained in a rat model of cholestasis. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G615-G622 (2007). *

• Lou G, Li Y, Chen B, Chen M, Chen J, Liao R, Zhang Y, Wang Y, Zhou D. Functional analysis on the 5'-flanking region of human FXR gene in HepG2 cells. Gene 396: 358-368 (2007). *

• Love MW, Craddock AL, Angelin B, Brunzell JD, Duane WC, Dawson PA. Analysis of the ileal bile acid transporter gene, SLC10A2, in subjects with familial hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21: 2039-2045 (2001). *

• Lovisetto P, Raviolo P. Intrahepatic cholestasis caused by biochemical errors of bile acids. Part I - Nosographic, pathogenetic, diagnostic features. Minerva Med. 85: 589-596 (1994).

• Lovisetto P, Raviolo P. Intrahepatic cholestasis due to biochemical errors of bile acids. II. Clinical and therapeutic aspects. Minerva Med. 85: 639-646 (1994).

• Lundasen T, Andersson EM, Schreyer S, Ostlund-Lindqvist AM, Angelin B, Rudling M. Ileal bile acid transport inhibition lowers plasma glucose and lipid levels in ob/ob mice. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 45 (2006). *

• Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260: 530-536 (2006). *

• Lundell K, Wikvall K. Species-specific and age-dependent bile acid composition: aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr. Drug Metab. 9: 323-331 (2008).

• Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116: 1102-1109 (2006). *

• Mackenzie PI, Rogers A, Treloar J, Jorgensen BR, Miners JO, Meech R. Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J. Biol. Chem. 283: 36205-36210 (2008). *

• Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J. Hepatol. 51: 528-534 (2009).

• Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem. Pharmacol. 72: 512-522 (2006). *

• Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J. Pharmacol. Sci. 97: 177-183 (2005). *

• Makowski P, Pikula S. Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobiotics. Pol. J. Pharmacol. 49: 387-394 (1997).

• Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. L-Carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am. J. Gastroenterol. Jan 12 [Epub ahead of print] (2010). *

• Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell. Mol. Life Sci. 61: 393-416 (2004). *

• Mano Y, Usui T, Kamimura H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Dispos. 28: 13-18 (2006). *

• Marin JJ. How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion. World J. Gastroenterol. 14: 5617-5619 (2008). *

• Marin JJG, Romero MR, Vallejo M, Perez MJ, Briz O. Emerging interest in bile acid transporters in pathophysiology and pharmacology. Med. Hypotheses Res. 2: 425-448 (2005). *

• Markovich D. Sulfate transport by SLC26 transporters. Novartis Found. Symp. 273: 42-51 (2006).

• Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485 (2005). *

• Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J. 391: 549-560 (2005). *

• Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein (L-FABP) gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G36-G48 (2006). *

• Martinez LO, Jacquet S, Terce F, Collet X, Perret B, Barbaras R. New insight on the molecular mechanisms of high-density lipoprotein cellular interactions. Cell. Mol. Life Sci. 61: 2343-2360 (2004). *

• Masson D, Lagrost L, Athias A, Gambert P, Brimer-Cline C, Lan L, Schuetz JD, Schuetz EG, Assem M. Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler. Thromb. Vasc. Biol. 25: 2164-2169 (2005). *

• Masson D, Qatanani M, Sberna AL, Xiao R, Pais de Barros JP, Grober J, Deckert V, Athias A, Gambert P, Lagrost L, Moore DD, Assem M. Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. J. Lipid Res. 49: 1682-1691 (2008). *

• Mataki C, Magnier BC, Houten SM, Annicotte JS, Argmann C, Thomas C, Overmars H, Kulik W, Metzger D, Auwerx J, Schoonjans K. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol. Cell Biol. 27: 8330-8339 (2007). *

• Mato JM, Martinez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu. Rev. Nutr. 28: 273-293 (2008). *

• Mazumder I, Mahato SB. Bile acid transformations by Alcaligenes recti. Steroids 58: 79-86 (1993).

• Mazzella G, Fusaroli P, Pezzoli A, Azzaroli F, Mazzeo C, Zambonin L, Simoni P, Festi D, Roda E. Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. Dig. Dis. Sci. 44: 2478-2483 (1999). *

• Mazzella G, Parini P, Bazzoli F, Villanova N, Festi D, Aldini R, Roda A, Cipolla A, Polimeni C, Tonelli D, et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig. Dis. Sci. 38: 896-902 (1993).

• Mazzella G, Rizzo N, Azzaroli F, Simoni P, Bovicelli L, Miracolo A, Simonazzi G, Colecchia A, Nigro G, Mwangemi C, Festi D, Roda E. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 33: 504-508 (2001). *

• McCarthy TC, Li X, Sinal CJ. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein-3 gene expression by bile acids. J. Biol. Chem. 280: 23232-23242 (2005). *

• McGarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J. Clin. Gastroenterol. 39: 98-109 (2005).

• McNeil CJ, Hay SM, Rucklidge GJ, Reid M, Duncan G, Maloney CA, Rees WD. Disruption of lipid metabolism in the liver of the pregnant rat fed folate-deficient and methyl donor-deficient diets. Br. J. Nutr. 99: 262-271 (2008). *

• Melter M, Rodeck B, Kardorff R, Hoyer PF, Petersen C, Ballauff A, Brodehl J. Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am. J. Gastroenterol. 95: 3522-3528 (2000). *

• Mencarelli A, Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J. Cell. Mol. Med. Dec 11 [Epub ahead of print] (2009).

• Mendez-Gonzalez J, Suren-Castillo S, Calpe-Berdiel L, Rotllan N, Vazquez-Carrera M, Escola-Gil JC, Blanco-Vaca F. Disodium ascorbyl phytostanol phosphate (FM-VP4), a modified phytostanol, is a highly active hypocholesterolaemic agent that affects the enterohepatic circulation of both cholesterol and bile acids in mice. Br. J. Nutr. 103: 153-160 (2010). *

• Mendez-Sanchez N, Panduro A, Murguia D, Rincon AR, Uribe M. Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann. Hepatol. 1: 85-89 (2002). *

• Meng LJ, Reyes H, Palma J, Hernandez I, Ribalta J, Sjovall J. Profiles of bile acids and progesterone metabolites in the urine and serum of women with intrahepatic cholestasis of pregnancy. J. Hepatol. 27: 346-357 (1997). *

• Meng LJ, Reyes H, Palma J, Hernandez I, Ribalta J, Sjovall J. Effects of ursodeoxycholic acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy. J. Hepatol. 27: 1029-1040 (1997). *

• Miao J, Fang S, Bae Y, Kemper JK. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. J. Biol. Chem. 281: 14537-14546 (2006). *

• Miao J, Fang S, Lee J, Comstock C, Knudsen KE, Kemper JK. Functional specificity of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol. Cell. Biol. 29: 6170-6181 (2009). *

• Michaels A, Levy C. The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61 (2008). *

• Mieli-Vergani G, Vergani D. Liver transplantation in metabolic liver diseases. J. Gastroenterol. Hepatol. 19: S396-S397 (2004). *

• Miettinen TE, Tarpila S, Gylling H. The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones. Hepatology 25: 514-518 (1997). *

• Milnes MR, Garcia A, Grossman E, Grun F, Shiotsugu J, Tabb MM, Kawashima Y, Katsu Y, Watanabe H, Iguchi T, Blumberg B. Activation of steroid and xenobiotic receptor (SXR, NR1I2) and its orthologs in laboratory, toxicologic, and genome model species. Environ. Health Perspect. 116: 880-885 (2008). *

• Miyata M, Watase H, Hori W, Shimada M, Nagata K, Gonzalez FJ, Yamazoe Y. Role for enhanced faecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity. Xenobiotica 36: 631-644 (2006). *

• Modica S, Bellafante E, Moschetta A. Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. Front. Biosci. 14: 4719-4745 (2009).

• Modica S, Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett. 580: 5492-5499 (2006). *

• Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 68: 9589-9594 (2008). *

• Mohan R, Heyman RA. Orphan nuclear receptor modulators. Curr. Top. Med. Chem. 3: 1637-1647 (2003).

• Molino G, Hofmann AF, Cravetto C, Belforte G, Bona B. Simulation of the metabolism and enterohepatic circulation of endogenous chenodeoxycholic acid in man using a physiological pharmacokinetic model. Eur. J. Clin. Invest. 16: 397-414 (1986).

• Monte MJ, Fernandez-Tagarro M, Macias RI, Jimenez F, Gonzalez-San Martin F, Marin JJ. Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clin. Sci. (Lond.) 109: 199-207 (2005). *

• Moore JT, Goodwin B, Willson TM, Kliewer SA. Nuclear receptor regulation of genes involved in bile acid metabolism. Crit. Rev. Eukaryot. Gene Expr. 12: 119-135 (2002).

• Moran JM, Salas J, Botello F, Macia E, Climent V. Taurine and cholestasis associated to TPN. Experimental study in rabbit model. Pediatr. Surg. Int. 21: 786-792 (2005).

• Moreno M, Molina H, Amigo L, Zanlungo S, Arrese M, Rigotti A, Miquel JF. Hepatic overexpression of caveolins increases bile salt secretion in mice. Hepatology 38: 1477-1488 (2003). *

• Moschetta A. Welcoming Foxa2 in the bile acid entourage. Cell. Metab. 8: 276-278 (2008). *

• Moschetta A, Kliewer SA. Weaving betaKlotho into bile acid metabolism. J. Clin. Invest. 115: 2075-2077 (2005). *

• Motojima K. 17beta-Hydroxysteroid dehydrogenase type 11 is a major peroxisome proliferator-activated receptor alpha-regulated gene in mouse intestine. Eur. J. Biochem. 271: 4141-4146 (2004). *

• Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 14: 7068-7074 (2008). *

• Moustafa MA, Ogino D, Nishimura M, Ueda N, Naito S, Furukawa M, Uchida T, Ikai I, Sawada H, Fukumoto M. Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma. Cancer Sci. 95: 530-536 (2004). *

• Murakami T, Walczak R, Caron S, Duhem C, Vidal V, Darteil R, Staels B. The farnesoid X receptor induces fetuin-B gene expression in human hepatocytes. Biochem. J. 407: 461-469 (2007). *

• Muratore CS, Harty MW, Papa EF, Tracy TF Jr. Dexamethasone alters the hepatic inflammatory cellular profile without changes in matrix degradation during liver repair following biliary decompression. J. Surg. Res. 156: 231-239 (2009). *

• Nagasaka H, Miida T, Hirano KI, Ota A, Murayama K, Yorifuji T, Kobayashi K, Takatani T, Tsukahara H, Hui SP, Takayanagi M, Chiba H. Fluctuation of lipoprotein metabolism linked with bile acid-activated liver nuclear receptors in Alagille syndrome. Atherosclerosis 198: 434-440 (2008).

• Nagengast FM. Bile acids and colonic carcinogenesis. Scand. J. Gastroenterol. 23: 76-81 (1988).

• Nakagaki M, Danzinger RG, Hofmann AF, DiPietro RA. Biliary secretion and hepatic metabolism of taurine-conjugated 7 alpha-hydroxy and 7 beta-hydroxy bile acids in the dog. Defective hepatic transport and bile hyposecretion. Gastroenterology 87: 647-659 (1984).

• Nakahara M, Fujii H, Maloney PR, Shimizu M, Sato R. Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA. J. Biol. Chem. 277: 37229-37234 (2002). *

• Nakamoto K, Wang S, Jenison RD, Guo GL, Klaassen CD, Wan YJ, Zhong XB. Linkage disequilibrium blocks, haplotype structure, and htSNPs of human CYP7A1 gene. BMC Genet. 7: 29 (2006). *

• Nakamura K, Aoshima M, Tani M, Kato T, Fugita M, Kimura A, Hasegawa T, Akiyama K, Makino I. Effect of ursodeoxycholic acid (UDCA) therapy for compensatory liver cirrhosis on liver function tests and serum bile acid metabolism. Nippon Shokakibyo Gakkai Zasshi 89: 2762-2770 (1992).

• Nakashima T, Sano A, Seto Y, Nakajima T, Shima T, Sakamoto Y, Okuno T, Kashima K, Hasegawa T. Unusual trihydroxy bile acids in the urine of patients treated with chenodeoxycholate, ursodeoxycholate or rifampicin and those with cirrhosis. Hepatology 11: 255-260 (1990).

• Nakashima T, Yoh T, Sumida Y, Kakisaka Y, Mitsuyoshi H. Differences in the efficacy of ursodeoxycholic acid and bile acid metabolism between viral liver diseases and primary biliary cirrhosis. J. Gastroenterol. Hepatol. 16: 541-547 (2001). *

• Newton DJ, Wang RW, Evans DC. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR(-) and EHBR rats. Life Sci. 77: 1106-1115 (2005). *

• Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell. Signal. 20: 2180-2197 (2008). *

• Nicolaou KC, Evans RM, Roecker AJ, Hughes R, Downes M, Pfefferkorn JA. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem. 1: 908-920 (2003).

• Nilsell K, Angelin B, Leijd B, Einarsson K. Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis. Gastroenterology 85: 1248-1256 (1983).

• Nishida S, Ozeki J, Makishima M. Modulation of bile acid metabolism by 1alpha-hydroxyvitamin D3 administration in mice. Drug Metab. Dispos. 37: 2037-2044 (2009). *

• Nishioka T, Hyogo H, Numata Y, Yamaguchi A, Kobuke T, Komichi D, Nonaka M, Inoue M, Nabeshima Y, Ogi M, Iwamoto K, Ishitobi T, Ajima T, Chayama K, Tazuma S. A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion. J. Atheroscler. Thromb. 12: 211-217 (2005). *

• Nishiura H, Kimura A, Yamato Y, Aoki K, Inokuchi T, Kurosawa T, Matsuishi T. Developmental pattern of urinary bile acid profile in preterm infants. Pediatr. Int. May 14 [Epub ahead of print] (2009).

• Nittono H, Takei H, Unno A, Kimura A, Shimizu T, Kurosawa T, Tohma S, Une M. Diagnostic determination system for high-risk screening for inborn errors of bile acid metabolism based on an analysis of urinary bile acids using gas chromatography-mass spectrometry: results for 10 years in Japan. Pediatr. Int. 51: 535-543 (2009). *

• Nojiri S, Nakao H, Sugauchi F, Miyaki T, Senda K, Sasaki M, Kataoka H, Kamiya T, Nakazawa T, Ohara H, Orito E, Joh T. Effect of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis C virus infection. Hepatol. Res. 39: 21-30 (2009). *

• Nolan DG, Martin LS, Natarajan S, Hume RF Jr. Fetal compromise associated with extreme fetal bile acidemia and maternal primary sclerosing cholangitis. Obstet. Gynecol. 84: 695-696 (1994).

• Nomiyama T, Bruemmer D. Liver X receptors as therapeutic targets in metabolism and atherosclerosis. Curr. Atheroscler. Rep. 10: 88-95 (2008).

• Nomoto M, Miyata M, Shimada M, Yoshinari K, Gonzalez FJ, Shibasaki S, Kurosawa T, Shindo Y, Yamazoe Y. ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output. Eur. J. Pharmacol. 574: 192-200 (2007). *

• Nomoto M, Miyata M, Yin S, Kurata Y, Shimada M, Yoshinari K, Gonzalez FJ, Suzuki K, Shibasaki S, Kurosawa T, Yamazoe Y. Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor. Biol. Pharm. Bull. 32: 172-178 (2009). *

• Norata GD, Catapano AL. Lipid lowering activity of drugs affecting cholesterol absorption. Nutr. Metab. Cardiovasc. Dis. 14: 42-51 (2004).

• Ogura M, Nishida S, Ishizawa M, Sakurai K, Shimizu M, Matsuo S, Amano S, Uno S, Makishima M. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J. Pharmacol. Exp. Ther. 328: 564-570 (2009). *

• Ohashi K, Yokoyama T, Yamato M, Kuge H, Kanehiro H, Tsutsumi M, Amanuma T, Iwata H, Yang J, Okano T, Nakajima Y. Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets. Nat. Med. 13: 880-885 (2007). *

• Ohno M. Functional analysis of nuclear receptor FXR controlling metabolism of cholesterol. Yakugaku Zasshi 128: 343-355 (2008). *

• Ohta Y, Kongo-Nishimura M, Imai Y, Kitagawa A. Melatonin attenuates disruption of serum cholesterol status in rats with a single alpha-naphthylisothiocyanate treatment. J. Pineal Res. 42: 159-165 (2007). *

• Okoli AS, Wilkins MR, Raftery MJ, Mendz GL. The response of Helicobacter hepaticus to bovine bile. J. Proteome Res. Jan 16 [Epub ahead of print] (2010). *

• Okuda H, Obata H, Nakanishi T, Hisamitsu T, Matsubara K, Watanabe H. Quantification of individual serum bile acids in patients with liver diseases using high-performance liquid chromatography. Hepatogastroenterology 31: 168-171 (1984).

• Ory DS. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ. Res. 95: 660-670 (2004). *

• Oshima H, Kon J, Ooe H, Hirata K, Mitaka T. Functional expression of organic anion transporters in hepatic organoids reconstructed by rat small hepatocytes. J. Cell. Biochem. 104: 68-81 (2008). *

• Owen BM, Milona A, van Mil S, Clements P, Holder J, Boudjelal M, Cairns W, Parker M, White R, Williamson C. Intestinal detoxification limits the activation of hepatic pregnane X receptor by lithocholic acid. Drug Metab. Dispos. 38: 143-149 (2010). *

• Palermo M, Marazzi MG, Hughes BA, Stewart PM, Clayton PT, Shackleton CH. Human delta(4)-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism. Steroids 73: 417-423 (2008).

• Pascussi JM, Gerbal-Chaloin S, Drocourt L, Assenat E, Larrey D, Pichard-Garcia L, Vilarem MJ, Maurel P. Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 34: 633-664 (2004).

• Pascussi JM, Vilarem MJ. Molecular mechanisms linking xenobiotic metabolism and inflammation. Med. Sci. (Paris) 24: 301-305 (2008).

• Patel DD, Knight BL, Soutar AK, Gibbons GF, Wade DP. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. Biochem. J. 351: 747-753 (2000). *

• Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17: 1671-1677 (2009). *

• Paumgartner G. Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J. Gastroenterol. 12: 4445-4451 (2006). *

• Pawar A, Botolin D, Mangelsdorf DJ, Jump DB. The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression. J. Biol. Chem. 278: 40736-40743 (2003). *

• Pawlikowska L, Groen A, Eppens EF, Kunne C, Ottenhoff R, Looije N, Knisely AS, Killeen NP, Bull LN, Oude Elferink RP, Freimer NB. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum. Mol. Genet. 13: 881-892 (2004). *

• Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93: 693-704 (1998). *

• Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17: 259-272 (2003). *

• Pircher PC, Kitto JL, Petrowski ML, Tangirala RK, Bischoff ED, Schulman IG, Westin SK. Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 278: 27703-27711 (2003). *

• Plosch T, Bloks VW, Terasawa Y, Berdy S, Siegler K, Van Der Sluijs F, Kema IP, Groen AK, Shan B, Kuipers F, Schwarz M, Schwartz M. Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor. Gastroenterology 126: 290-300 (2004). *

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. 21: 1840-1845 (2001). *

• Post SM, Groenendijk M, van der Hoogt CC, Fievet C, Luc G, Hoekstra M, Princen HM, Staels B, Rensen PC. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 26: 2724-2730 (2006).

• Poupon R. Molecular mechanisms of bile formation and cholestatic diseases. Bull. Acad. Natl. Med. 187: 1261-1274 (2003).

• Poupon RE, Ouguerram K, Chretien Y, Verneau C, Eschwege E, Magot T, Poupon R. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 17: 577-582 (1993).

• Prall RT, Lindor KD, Wiesner RH, LaRusso NF. Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2: 99-103 (2000).

• Purucker E, Marschall HU, Winograd R, Matern S. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. Biochim. Biophys. Acta 1526: 44-52 (2001). *

• Rader DJ. Liver X receptor and farnesoid X receptor as therapeutic targets. Am. J. Cardiol. 100: S15-S19 (2007). *

• Raedsch R, Lauterburg BH, Hofmann AF. Altered bile acid metabolism in primary biliary cirrhosis. Dig. Dis. Sci. 26: 394-401 (1981).

• Raicht RF, Cohen BI, Sarwal A, Takahashi M. Ursodeoxycholic acid. Effects on sterol metabolism in rats. Biochim. Biophys. Acta 531: 1-8 (1978).

• Raunio H, Hakkola J, Pelkonen O. Regulation of CYP3A genes in the human respiratory tract. Chem. Biol. Interact. 151: 53-62 (2005). *

• Read TE, Harris HW, Grunfeld C, Feingold KR, Kane JP, Rapp JH. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur. Heart J. 14 Suppl. K: 125-129 (1993).

• Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21: 193-230 (2001). *

• Redinger RN. Nuclear receptors in cholesterol catabolism: molecular biology of the enterohepatic circulation of bile salts and its role in cholesterol homeostasis. J. Lab. Clin. Med. 142: 7-20 (2003). *

• Redinger RN. The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: bile salts as ligands for nuclear hormone receptors. Can. J. Gastroenterol. 17: 265-271 (2003). *

• Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta Jan 6 [Epub ahead of print] (2010). *

• Repa JJ, Mangelsdorf DJ. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. 10: 557-563 (1999).

• Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16: 459-481 (2000). *

• Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: an estrogen-related disease. Semin. Liver Dis. 13: 289-301 (1993).

• Reyes H, Sjovall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann. Med. 32: 94-106 (2000).

• Rezen T, Tamasi V, Lovgren Sandblom A, Bjorkhem I, Meyer UA, Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse liver. BMC Genomics 10: 384 (2009). *

• Riccardi L, Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296: H272-H281 (2009). *

• Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJ, Moen CJ, Muller M, Frants RR, Kasanmoentalib S, Post SM, Princen HM, Porter JG, Katan MB, Hofker MH, Moore DD. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol. Endocrinol. 21: 1603-1616 (2007). *

• Rieger R, Oertelt S, Selmi C, Invernizzi P, Podda M, Gershwin ME. Decreased serum leptin levels in primary biliary cirrhosis: a link between metabolism and autoimmunity? Ann. N. Y. Acad. Sci. 1051: 211-217 (2005). *

• Rifai K, Hafer C, Rosenau J, Thmann CA, Haller H, Manns MP, Fliser D. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand. J. Gastroenterol. 41: 1212-1217 (2006). *

• Roda E, Aldini R, Mazzella G, Roda A, Sama C, Festi D, Barbara L. Enterohepatic circulation of bile acids after cholecystectomy. Gut 19: 640-649 (1978). *

• Rodrigues CM, Kren BT, Steer CJ, Setchell KD. Formation of delta 22-bile acids in rats is not gender specific and occurs in the peroxisome. J. Lipid Res. 37: 540-550 (1996). *

• Rodriguez-Ortigosa CM, Cincu RN, Sanz S, Ruiz F, Quiroga J, Prieto J. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut 50: 701-706 (2002). *

• Roglans N, Vazquez-Carrera M, Alegret M, Novell F, Zambon D, Ros E, Laguna JC, Sanchez RM. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur. J. Clin. Pharmacol. 59: 855-861 (2004). *

• Rogler G. Significance of anti-inflammatory effects of PPARgamma agonists? Gut 55: 1067-1069 (2006). *

• Roy CC, Weber AM, Morin CL, Lepage G, Brisson G, Yousef I, Lasalle R. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J. Pediatr. Gastroenterol. Nutr. 1: 469-478 (1982).

• Rudling M, Parini P, Angelin B. Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat. J. Clin. Invest. 99: 2239-2245 (1997). *

• Ruiz ML, M Villanueva SS, Luquita MG, Sanchez-Pozzi EJ, Crocenzi FA, Pellegrino JM, Ochoa JE, Vore M, Mottino AD, Catania VA. Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2. Biochem. Pharmacol. 69: 531-539 (2005). *

• Ruiz-Gaspa S, Guanabens N, Enjuanes A, Peris P, Martinez-Ferrer A, de Osaba MJ, Gonzalez B, Alvarez L, Monegal A, Combalia A, Pares A. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur. J. Clin. Invest. 40: 25-34 (2010). *

• Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J. Lipid Res. 50: S120-S125 (2009). *

• Rutgeerts P, Ghoos Y, Vantrappen G. Kinetics of primary bile acids in patients with non-operated Crohn's disease. Eur. J. Clin. Invest. 12: 135-143 (1982).

• Sanchez-Mete L, Attili AF. Cholelithiasis: genetic hypothesis. Minerva Gastroenterol. Dietol. 46: 45-55 (2000).

• Sandhu BS, Luketic VA. Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849 (2006). *

• Sanyal S, Bavner A, Haroniti A, Nilsson LM, Lundasen T, Rehnmark S, Witt MR, Einarsson C, Talianidis I, Gustafsson JA, Treuter E. Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 104: 15665-15670 (2007). *

• Sato M, Sato K, Furuse M. Change in hepatic and plasma bile acid contents and its regulatory gene expression in the chicken embryo. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 150: 344-347 (2008). *

• Sauer P, Kloters-Plachky P, Stiehl A. Inhibition of ileal bile acid transport by cyclosporin A in rat. Eur. J. Clin. Invest. 25: 677-682 (1995).

• Sauer P, Rudolph G, Endele R, Senn M, Theilmann L, Otto G, Stremmel W, Stiehl A. Kinetics of primary bile acids in patients after orthotopic liver transplantation. Eur. J. Clin. Invest. 26: 979-982 (1996).

• Savkur RS, Thomas JS, Bramlett KS, Gao Y, Michael LF, Burris TP. Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alpha. J. Pharmacol. Exp. Ther. 312: 170-178 (2005). *

• Schaffner F. The history of liver disease at The Mount Sinai Hospital. Mt. Sinai J. Med. 67: 76-83 (2000). *

• Schliess F, Haussinger D. Osmosensing by integrins in rat liver. Methods Enzymol. 428: 129-144 (2007). *

• Schlosser PM, Borghoff SJ, Coldham NG, David JA, Ghosh SK. Physiologically-based pharmacokinetic modeling of genistein in rats, part I: model development. Risk Anal. 26: 483-500 (2006). *

• Schmassmann A, Angellotti MA, Clerici C, Hofmann AF, Ton-Nu HT, Schteingart CD, Marcus SN, Hagey LR, Rossi SS, Aigner A. Transport, metabolism, and effect of chronic feeding of lagodeoxycholic acid. A new, natural bile acid. Gastroenterology 99: 1092-1104 (1990).

• Schmassmann A, Fehr HF, Locher J, Lillienau J, Schteingart CD, Rossi SS, Hofmann AF. Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans. Gastroenterology 104: 1171-1181 (1993).

• Schmidt DR, Mangelsdorf DJ. Nuclear receptors of the enteric tract: guarding the frontier. Nutr. Rev. 66: S88-S97 (2008). *

• Schmuth M, Elias PM, Feingold KR. Beyond glucocorticoids, retinoids and vitamin D - the evolution of nuclear hormone type transcription factor targeting in the skin. J. Dtsch. Dermatol. Ges. 1: 352-362 (2003).

• Schreibman I, Regev A. Recurrent primary biliary cirrhosis after liver transplantation - the disease and its management. MedGenMed. 8: 30 (2006). *

• Schuetz E, Strom S. Promiscuous regulator of xenobiotic removal. Nat. Med. 7: 536-537 (2001). *

• Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104 (1999). *

• Schwarz M, Lund EG, Lathe R, Bjorkhem I, Russell DW. Identification and characterization of a mouse oxysterol 7alpha-hydroxylase cDNA. J. Biol. Chem. 272: 23995-24001 (1997). *

• Schwarz M, Lund EG, Setchell KD, Kayden HJ, Zerwekh JE, Bjorkhem I, Herz J, Russell DW. Disruption of cholesterol 7alpha-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J. Biol. Chem. 271: 18024-18031 (1996). *

• Schwarz M, Russell DW, Dietschy JM, Turley SD. Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J. Lipid Res. 39: 1833-1843 (1998). *

• Schwarz M, Wright AC, Davis DL, Nazer H, Bjorkhem I, Russell DW. The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J. Clin. Invest. 106: 1175-1184 (2000). *

• Scotti E, Gilardi F, Godio C, Gers E, Krneta J, Mitro N, De Fabiani E, Caruso D, Crestani M. Bile acids and their signaling pathways: eclectic regulators of diverse cellular functions. Cell. Mol. Life Sci. 64: 2477-2491 (2007). *

• Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, Yueh MF, Bonzo JA, Argikar U, Kaeding J, Trottier J, Remmel RP, Ritter JK, Barbier OK, Tukey RH. Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab. Dispos. 35: 419-427 (2007). *

• Seo YK, Chung YT, Kim S, Echchgadda I, Song CS, Chatterjee B. Xenobiotic- and vitamin D-responsive induction of the steroid/bile acid-sulfotransferase Sult2A1 in young and old mice: the role of a gene enhancer in the liver chromatin. Gene 386: 218-223 (2007). *

• Setchell KD, Heubi JE, Bove KE, O'Connell NC, Brewsaugh T, Steinberg SJ, Moser A, Squires RH Jr. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 124: 217-232 (2003). *

• Setchell KD, Yamashita H, Rodrigues CM, O'Connell NC, Kren BT, Steer CJ. delta 22-Ursodeoxycholic acid, a unique metabolite of administered ursodeoxycholic acid in rats, indicating partial beta-oxidation as a major pathway for bile acid metabolism. Biochemistry 34: 4169-4178 (1995).

• Shafqat N, Marschall HU, Filling C, Nordling E, Wu XQ, Bjork L, Thyberg J, Martensson E, Salim S, Jornvall H, Oppermann U. Expanded substrate screenings of human and Drosophila type 10 17beta-hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism. Biochem. J. 376: 49-60 (2003). *

• Shefer S, Zaki FG, Salen G. Early morphologic and enzymatic changes in livers of rats treated with chenodeoxycholic and ursodeoxycholic acids. Hepatology 3: 201-208 (1983).

• Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat. Genet. 27: 375-382 (2001). *

• Shimomura M, Masuda S, Goto M, Katsura T, Kiuchi T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K. Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. Drug Metab. Pharmacokinet. 23: 313-317 (2008).

• Shin DJ, Campos JA, Gil G, Osborne TF. PGC-1alpha activates CYP7A1 and bile acid biosynthesis. J. Biol. Chem. 278: 50047-50052 (2003). *

• Shin OJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J. Biol. Chem. 284: 11110-11120 (2009). *

• Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, Yokoi T, Yoshizato K, Suzuki H. Bezafibrate induces multidrug-resistance P-glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol. Res. 37: 548-556 (2007). *

• Shoda J, Tanaka N, Osuga T, Matsuura K, Miyazaki H. Altered bile acid metabolism in liver disease: concurrent occurrence of C-1 and C-6 hydroxylated bile acid metabolites and their preferential excretion into urine. J. Lipid Res. 31: 249-259 (1990). *

• Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731-744 (2000). *

• Sinal CJ, Yoon M, Gonzalez FJ. Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids. J. Biol. Chem. 276: 47154-47162 (2001). *

• Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, Darteil R, Hum DW, Fruchart JC, Staels B. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett. 566: 173-177 (2004). *

• Sirvent A, Verhoeven AJ, Jansen H, Kosykh V, Darteil RJ, Hum DW, Fruchart JC, Staels B. Farnesoid X receptor represses hepatic lipase gene expression. J. Lipid Res. 45: 2110-2115 (2004). *

• Sjovall J. Fifty years with bile acids and steroids in health and disease. Lipids 39: 703-722 (2004).

• Smit MJ, Temmerman AM, Wolters H, Kuipers F, Beynen AC, Vonk RJ. Dietary fish oil-induced changes in intrahepatic cholesterol transport and bile acid synthesis in rats. J. Clin. Invest. 88: 943-951 (1991). *

• Smit MJ, Verkade HJ, Havinga R, Vonk RJ, Scherphof GL, In 't Veld G, Kuipers F. Dietary fish oil potentiates bile acid-induced cholesterol secretion into bile in rats. J. Lipid Res. 35: 301-310 (1994). *

• Soccio RE, Breslow JL. Intracellular cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 24: 1150-1160 (2004). *

• Sogawa K, Yamada T, Suzuki Y, Masaki T, Watanabe S, Uchida Y, Arima K, Nishioka M, Matsumoto K. Elevation of ceruloplasmin activity involved in changes of hepatic metal concentration in primary biliary cirrhosis. Res. Commun. Chem. Pathol. Pharmacol. 84: 367-370 (1994).

• Soisson SM, Parthasarathy G, Adams AD, Sahoo S, Sitlani A, Sparrow C, Cui J, Becker JW. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl. Acad. Sci. U.S.A. 105: 5337-5342 (2008). *

• Sokal EM, Smets F, Bourgois A, Van Maldergem L, Buts JP, Reding R, Bernard Otte J, Evrard V, Latinne D, Vincent MF, Moser A, Soriano HE. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 76: 735-738 (2003).

• Sokolovic D, Bjelakovic G, Nikolic J, Djindjic B, Pavlovic D, Kocic G, Stojanovic I, Pavlovic V. Effect of L-arginine on metabolism of polyamines in rat's brain with extrahepatic cholestasis. Amino Acids Jan 29 [Epub ahead of print] (2008). *

• Sokolovic D, Bjelakovic G, Nikolic J, Djindjic B, Pavlovic D, Kocic G, Stojanovic I, Pavlovic V. Effect of L-arginine on metabolism of polyamines in rat's brain with extrahepatic cholestasis. Amino Acids Mar 13 [Epub ahead of print] (2009). *

• Song CS, Echchgadda I, Baek BS, Ahn SC, Oh T, Roy AK, Chatterjee B. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 276: 42549-42556 (2001). *

• Song CS, Echchgadda I, Seo YK, Oh T, Kim S, Kim SA, Cho S, Shi L, Chatterjee B. An essential role of the CAAT/enhancer binding protein-alpha in the vitamin D induced expression of the human steroid/bile acid-sulfotransferase (SULT2A1). Mol. Endocrinol. 20: 795-808 (2006). *

• Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, Evans RM. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc. Natl. Acad. Sci. U.S.A. 102: 2198-2203 (2005). *

• Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc. Natl. Acad. Sci. U.S.A. 99: 13801-13806 (2002). *

• Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67: 1383-1392 (2007).

• Stahl S, Davies MR, Cook DI, Graham MJ. Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis. Xenobiotica 38: 725-777 (2008). *

• Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab. Dispos. 29: 1467-1472 (2001). *

• Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 98: 3369-3374 (2001). *

• Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146: 984-991 (2005). *

• Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM, Downes M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U.S.A. 103: 11323-11328 (2006). *

• Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J. Biol. Chem. 279: 11336-11343 (2004). *

• Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U.S.A. 102: 2063-2068 (2005). *

• Stellaard F. Use of dual isotope tracers in biomedical research. Isotopes Environ. Health Stud. 41: 275-286 (2005).

• Stiehl A. Pathophysiology of cholestasis: correlation between bile acid metabolism and liver damage. Z. Gastroenterol. 30 Suppl. 1: 46-48 (1992).

• Stiehl A. Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment. Ital. J. Gastroenterol. 27: 193-195 (1995).

• Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, Marz W, Trauner M. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46: 776-784 (2007). *

• Strassburg CP. Autoimmune liver diseases. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 66-70 (2005). *

• Stroup D. Kinase/phosphatase regulation of CYP7A1. Front. Biosci. 10: 1678-1692 (2005).

• Sturm E, Wagner M, Trauner M. Nuclear receptor ligands in therapy of cholestatic liver disease. Front. Biosci. 14: 4299-4325 (2009).

• Subramaniam P, Clayton PT, Portmann BC, Mieli-Vergani G, Hadzic N. Variable clinical spectrum of the most common inborn error of bile acid metabolism - 3beta-hydroxy-Delta5-C27-steroid dehydrogenase deficiency. J. Pediatr. Gastroenterol. Nutr. 50: 61-66 (2010).

• Suh JI. Role of PXR and CAR in cholestasis. Korean J. Hepatol. 12: 5-15 (2006).

• Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 32: 1239-1246 (2004). *

• Suzuki S, Hashizume K. Do PPARgamma ligands suppress the growth of cholangiocarcinoma or the cholangiohepatitis induced by the tumor? PPAR Res. 2008: 587401 (2008). *

• Swann J, Wang Y, Abecia L, Costabile A, Tuohy K, Gibson G, Roberts D, Sidaway J, Jones H, Wilson ID, Nicholson J, Holmes E. Gut microbiome modulates the toxicity of hydrazine: a metabonomic study. Mol. Biosyst. 5: 351-355 (2009). *

• Tada N. Physiological actions of diacylglycerol outcome. Curr. Opin. Clin. Nutr. Metab. Care 7: 145-149 (2004).

• Tagliacozzi D, Mozzi AF, Casetta B, Bertucci P, Bernardini S, Di Ilio C, Urbani A, Federici G. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin. Chem. Lab. Med. 41: 1633-1641 (2003).

• Tan Y, Hughes D, Wang X, Costa RH. Adenovirus-mediated increase in HNF-3beta or HNF-3alpha shows differences in levels of liver glycogen and gene expression. Hepatology 35: 30-39 (2002). *

• Tanaka A, Leung PS, Kenny TP, Au-Young J, Prindiville T, Coppel RL, Ansari AA, Gershwin ME. Genomic analysis of differentially expressed genes in liver and biliary epithelial cells of patients with primary biliary cirrhosis. J. Autoimmun. 17: 89-98 (2001). *

• Tang W, Norlin M, Wikvall K. Glucocorticoid receptor-mediated upregulation of human CYP27A1, a potential anti-atherogenic enzyme. Biochim. Biophys. Acta 1781: 718-723 (2008). *

• Tazawa Y, Abukawa D, Sakamoto O, Nagata I, Murakami J, Iizuka T, Okamoto M, Kimura A, Kurosawa T, Iinuma K, Kobayashi K, Saheki T, Ohura T. A possible mechanism of neonatal intrahepatic cholestasis caused by citrin deficiency. Hepatol. Res. 31: 168-171 (2005).

• Tazawa Y, Yamada M, Nakagawa M, Konno T, Tada K. Serum bile acid patterns determined by an enzymatic method and high-performance liquid chromatography in young infants with cholestasis. J. Pediatr. Gastroenterol. Nutr. 3: 394-401 (1984).

• Temel RE, Lee RG, Kelley KL, Davis MA, Shah R, Sawyer JK, Wilson MD, Rudel LL. Intestinal cholesterol absorption is substantially reduced in mice deficient in both ATP-binding cassette transporter A1 (ABCA1) and Acyl-CoA:Cholesterol O-acyltransferase 2 (ACAT2). J. Lipid Res. 46: 2423-2431 (2005). *

• Tenenbaum A, Fisman EZ, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv. Cardiol. 45: 127-153 (2008).

• Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc. Diabetol. 5: 20 (2006). *

• Teng S, Piquette-Miller M. Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br. J. Pharmacol. 151: 367-376 (2007). *

• Thistle JL, LaRusso NF, Hofmann AF, Turcotte J, Carlson GL, Ott BJ. Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man. A dose-response study. Dig. Dis. Sci. 27: 161-168 (1982).

• Thomas C, Auwerx J, Schoonjans K. Bile acids and the membrane bile acid receptor TGR5 - connecting nutrition and metabolism. Thyroid 18: 167-174 (2008).

• Thompson PA, Wertheim BC, Roe DJ, Ashbeck EL, Jacobs ET, Lance P, Martinez ME, Alberts DS. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev. Res. (Phila. Pa) 2: 1023-1030 (2009).

• Tichauer JE, Morales MG, Amigo L, Galdames L, Klein A, Quinones V, Ferrada C, Alvarez AR, Rio MC, Miquel JF, Rigotti A, Zanlungo S. Overexpression of the cholesterol-binding protein MLN64 induces liver damage in the mouse. World J. Gastroenterol. 13: 3071-3079 (2007). *

• Tiemann M, Han Z, Soccio R, Bollineni J, Shefer S, Sehayek E, Breslow JL. Cholesterol feeding of mice expressing cholesterol 7alpha-hydroxylase increases bile acid pool size despite decreased enzyme activity. Proc. Natl. Acad. Sci. U.S.A. 101: 1846-1851 (2004). *

• Tiwari A, Maiti P. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discov. Today 14: 523-530 (2009).

• Toiviainen-Salo S, Durie PR, Numminen K, Heikkila P, Marttinen E, Savilahti E, Makitie O. The natural history of Shwachman-Diamond syndrome-associated liver disease from childhood to adulthood. J. Pediatr. 155: 807-811.e2 (2009).

• Tomaszewski P, Kubiak-Tomaszewska G, Pachecka J. Cytochrome P450 polymorphism - molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. Acta Pol. Pharm. 65: 307-318 (2008).

• Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? Hepatology 40: 260-263 (2004). *

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 18: 314-329 (2002).

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *

• Trauner M, Fickert P, Moustafa T, Guelly C, Fuchsbichler A, Denk H, Wagner M, Zollner G. Side chain-shortened bile acids for the treatment of cholestasis: lessons from nor-ursodeoxycholic acid. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 77-78 (2006). *

• Tsai PL, Tsai TH. Hepatobiliary excretion of berberine. Drug Metab. Dispos. 32: 405-412 (2004). *

• Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG. Malnutrition in end stage liver disease: recommendations and nutritional support. J. Gastroenterol. Hepatol. 23: 527-533 (2008). *

• Tu H, Okamoto AY, Shan B. FXR, a bile acid receptor and biological sensor. Trends Cardiovasc. Med. 10: 30-35 (2000).

• Turkoski BB. An ounce of prevention. Drugs used to treat hyperlipidemia (Part 1). Orthop. Nurs. 23: 58-61 (2004).

• Uchida K, Nomura Y, Kadowaki M, Arisue K, Takeuchi N, Ishikawa Y. Effects of sodium ursodeoxycholate, hyodeoxycholate and dehydrocholate on cholesterol and bile acid metabolism in rats. J. Pharmacobiodyn. 6: 346-357 (1983).

• Ulven SM, Dalen KT, Gustafsson JA, Nebb HI. LXR is crucial in lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids 73: 59-63 (2005). *

• Unno A, Takada I, Takezawa S, Oishi H, Baba A, Shimizu T, Tokita A, Yanagisawa J, Kato S. TRRAP as a hepatic coactivator of LXR and FXR function. Biochem. Biophys. Res. Commun. 327: 933-938 (2005). *

• Urizar NL, Dowhan DH, Moore DD. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J. Biol. Chem. 275: 39313-39317 (2000). *

• Vallim TQ, Edwards PA. Bile acids have the gall to function as hormones. Cell. Metab. 10: 162-164 (2009). *

• van Berkel TJ. Bringing retinoid metabolism into the 21st century. J. Lipid Res. 50: 2337-2339 (2009). *

• van der Leij FR, Bloks VW, Grefhorst A, Hoekstra J, Gerding A, Kooi K, Gerbens F, Te Meerman G, Kuipers F. Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. Genomics 90: 680-689 (2007). *

• van Dijk TH, Grefhorst A, Oosterveer MH, Bloks VW, Staels B, Reijngoud DJ, Kuipers F. An increased flux through the glucose-6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice. J. Biol. Chem. 284: 10315-10323 (2009). *

• van Mil SW, Houwen RH, Klomp LW. Genetics of familial intrahepatic cholestasis syndromes. J. Med. Genet. 42: 449-463 (2005). *

• van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V, Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White R, Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133: 507-516 (2007). *

• Vantrappen G, Ghoos Y, Rutgeerts P, Janssens J. Bile acid studies in uncomplicated Crohn's disease. Gut 18: 730-735 (1977). *

• Venteclef N, Delerive P. Interleukin-1 receptor antagonist induction as an additional mechanism for liver receptor homolog-1 to negatively regulate the hepatic acute phase response. J. Biol. Chem. 282: 4393-4399 (2007). *

• Venteclef N, Haroniti A, Tousaint JJ, Talianidis I, Delerive P. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J. Biol. Chem. 283: 3694-3701 (2008). *

• Verreault M, Kaeding J, Caron P, Trottier J, Grosse L, Houssin E, Paquet S, Perreault M, Barbier O. Regulation of endobiotics glucuronidation by ligand-activated transcription factors: physiological function and therapeutic potential. Drug Metab. Rev. Oct 15 [Epub ahead of print] (2009). *

• Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabiles N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 110: 3259-3269 (2004). *

• Versieck J, Hoste J, Vanballenberghe L, Barbier F, Cornelis R, Waelput I. Serum molybdenum in diseases of the liver and biliary system. J. Lab. Clin. Med. 97: 535-544 (1981).

• Vierling JM. Immune disorders of the liver and bile duct. Gastroenterol. Clin. North Am. 21: 427-449 (1992).

• Villalon L, Tuchweber B, Yousef IM. Low protein diets potentiate lithocholic acid-induced cholestasis in rats. J. Nutr. 122: 1587-1596 (1992). *

• Vitek L, Zelenka J, Zadinova M, Malina J. The impact of intestinal microflora on serum bilirubin levels. J. Hepatol. 42: 238-243 (2005). *

• Volle DH, Duggavathi R, Magnier BC, Houten SM, Cummins CL, Lobaccaro JM, Verhoeven G, Schoonjans K, Auwerx J. The small heterodimer partner is a gonadal gatekeeper of sexual maturation in male mice. Genes Dev. 21: 303-315 (2007). *

• Wakabayashi Y, Lippincott-Schwartz J, Arias IM. Intracellular trafficking of bile salt export pump (ABCB11) in polarized hepatic cells: constitutive cycling between the canalicular membrane and rab11 positive endosomes. Mol. Biol. Cell 15: 3485-3496 (2004). *

• Wan YJ, An D, Cai Y, Repa JJ, Hung-Po Chen T, Flores M, Postic C, Magnuson MA, Chen J, Chien KR, French S, Mangelsdorf DJ, Sucov HM. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol. Cell. Biol. 20: 4436-4444 (2000). *

• Wang DQ, Zhang L, Wang HH. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochim. Biophys. Acta 1733: 90-99 (2005). *

• Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42: 1331-1357 (2003).

• Wang L, Zhang D, Swaminathan A, Xue Y, Cheng PT, Wu S, Mosqueda-Garcia R, Aurang C, Everett DW, Humphreys WG. Glucuronidation as a major metabolic clearance pathway of 14C-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. Drug Metab. Dispos. 34: 427-439 (2006). *

• Wang M, Chen M, Zheng G, Dillard Iii B, Tallarico M, Ortiz Z, Holterman AX. Transcriptional activation by growth hormone of HNF-6-regulated hepatic genes, a potential mechanism for improved liver repair during biliary injury in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G357-G366 (2008). *

• Wang M, Tan Y, Costa RH, Holterman AX. In vivo regulation of murine CYP7A1 by HNF-6: a novel mechanism for diminished CYP7A1 expression in biliary obstruction. Hepatology 40: 600-608 (2004). *

• Wang XJ, Chamberlain MP, Vassieva O, Henderson CJ, Wolf CR. Relationship between hepatic phenotype and changes in gene expression in the cytochrome P450 reductase (POR) null mice. Biochem. J. 388: 857-867 (2005). *

• Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, Crumbley C, Garcia-Ordonez RA, Stayrook KR, Zhang X, Novick S, Chalmers MJ, Griffin PR, Burris TP. Modulation of RORalpha and RORgamma activity by 7-oxygenated sterol ligands. J. Biol. Chem. Dec 4 [Epub ahead of print] (2009). *

• Wang YD, Chen WD, Huang W. FXR, a target for different diseases. Histol. Histopathol. 23: 621-627 (2008). *

• Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 18: 1087-1095 (2008). *

• Warchol M, Car L, Grill JP, Schneider F. Metabolic changes in Clostridium absonum ATCC 27555 accompanying induction of epimerization of a primary bile acid. Curr. Microbiol. 47: 425-430 (2003).

• Warner FJ. Liver anti-inflammatory pathways: potential ways to control liver damage. Hepatology 45: 1327-1329 (2007). *

• Watanabe T, Asaka S, Kitagawa D, Saito K, Kurashige R, Sasado T, Morinaga C, Suwa H, Niwa K, Henrich T, Hirose Y, Yasuoka A, Yoda H, Deguchi T, Iwanami N, Kunimatsu S, Osakada M, Loosli F, Quiring R, Carl M, Grabher C, Winkler S, Del Bene F, Wittbrodt J,. Mutations affecting liver development and function in Medaka, Oryzias latipes, screened by multiple criteria. Mech. Dev. 121: 791-802 (2004). *

• Watkins RE, Noble SM, Redinbo MR. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr. Opin. Drug Discov. Devel. 5: 150-158 (2002).

• Weber AM, Roy CC. Bile acid metabolism in children with cystic fibrosis. Acta Paediatr. Scand. Suppl. 317: 9-15 (1985).

• Wei J, Qiu de K, Ma X. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. J. Dig. Dis. 10: 85-90 (2009). *

• Wertheim BC, Martínez ME, Ashbeck EL, Roe DJ, Jacobs ET, Alberts DS, Thompson PA. Physical activity as a determinant of fecal bile acid levels. Cancer Epidemiol. Biomarkers Prev. 18: 1591-1598 (2009). *

• Westin MA, Alexson SE, Hunt MC. Molecular cloning and characterization of two mouse peroxisome proliferator-activated receptor alpha (PPARa) regulated peroxisomal acyl-CoA thioesterases. J. Biol. Chem. 279: 21841-21848 (2004). *

• Wiesner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 88: 108-114 (1985).

• Wietholtz H, Marschall HU, Sjovall J, Matern S. Stimulation of bile acid 6 alpha-hydroxylation by rifampin. J. Hepatol. 24: 713-718 (1996). *

• Williams CN. Bile-acid metabolism and the liver. Clin. Biochem. 9: 149-152 (1976).

• Wills MR, Savory J. Vitamin D metabolism and chronic liver disease. Ann. Clin. Lab. Sci. 14: 189-197 (1984).

• Willson TM, Jones SA, Moore JT, Kliewer SA. Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med. Res. Rev. 21: 513-522 (2001). *

• Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K, Beltowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy. Hig. Med. Dosw. (Online) 61: 736-759 (2007). *

• Woollett LA, Buckley DD, Yao L, Jones PJ, Granholm NA, Tolley EA, Heubi JE. Effect of ursodeoxycholic acid on cholesterol absorption and metabolism in humans. J. Lipid Res. 44: 935-942 (2003). *

• Woudenberg J, Rembacz KP, van den Heuvel FA, Woudenberg-Vrenken TE, Buist-Homan M, Geuken M, Hoekstra M, Deelman LE, Enrich C, Henning RH, Moshage H, Faber KN. Caveolin-1 is enriched in the peroxisomal membrane of rat hepatocytes. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Wu JE, Basso F, Shamburek RD, Amar MJ, Vaisman B, Szakacs G, Joyce C, Tansey T, Freeman L, Paigen BJ, Thomas F, Brewer HB Jr, Santamarina-Fojo S. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but alter aortic atherosclerosis in transgenic mice. J. Biol. Chem. 279: 22913-22925 (2004). *

• Wu Z, Martin KO, Javitt NB, Chiang JY. Structure and functions of human oxysterol 7alpha-hydroxylase cDNAs and gene CYP7B1. J. Lipid Res. 40: 2195-2203 (1999). *

• Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U.S.A. 98: 3375-3380 (2001). *

• Xie Y, Newberry EP, Kennedy SM, Luo J, Davidson NO. Increased susceptibility to diet-induced gallstones in liver fatty acid binding protein (L-Fabp) knockout mice. J. Lipid Res. 50: 977-987 (2009). *

• Xing X, Burgermeister E, Geisler F, Einwachter H, Fan L, Hiber M, Rauser S, Walch A, Rocken C, Ebeling M, Wright MB, Schmid RM, Ebert MP. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. Hepatology 49: 979-988 (2009). *

• Yamaoka-Tojo M, Tojo T, Izumi T. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr. Vasc. Pharmacol. 6: 271-281 (2008).

• Yang L, Xiong A, He Y, Wang Z, Wang C, Wang Z, Li W, Yang L, Hu Z. Bile acids metabonomic study on the CCl(4)- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. Chem. Res. Toxicol. 21: 2280-2288 (2008). *

• Yehezkely-Schildkraut V, Munichor M, Mandel H, Berkowitz D, Hartman C, Eshach-Adiv O, Shamir R. Nonsyndromic paucity of interlobular bile ducts: report of 10 patients. J. Pediatr. Gastroenterol. Nutr. 37: 546-549 (2003). *

• Yousef IM, Perwaiz S, Lamireau T, Tuchweber B. Urinary bile acid profile in children with inborn errors of bile acid metabolism and chronic cholestasis; screening technique using electrospray tandem mass-spectrometry (ES/MS/MS). Med. Sci. Monit. 9: MT21-MT31 (2003). *

• Yu BZ, Kaimal R, Bai S, El Sayed KA, Tatulian SA, Apitz RJ, Jain MK, Deng R, Berg OG. Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A2: role in hypocholesterolemia. J. Nat. Prod. 72: 24-28 (2009).

• Yu C, Wang F, Jin C, Huang X, McKeehan WL. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J. Biol. Chem. 280: 17707-17714 (2005). *

• Yu L, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J. Lipid Res. 46: 1739-1744 (2005). *

• Zanlungo S, Rigotti A. Determinants of transhepatic cholesterol flux and their relevance for gallstone formation. Liver Int. 29: 323-330 (2009). *

• Zanlungo S, Rigotti A, Nervi F. Hepatic cholesterol transport from plasma into bile: implications for gallstone disease. Curr. Opin. Lipidol. 15: 279-286 (2004).

• Zhang EY, Phelps MA, Banerjee A, Khantwal CM, Chang C, Helsper F, Swaan PW. Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry 43: 11380-11392 (2004). *

• Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279: 49517-49522 (2004). *

• Zhang XY, Guan YF. Farnesoid X receptor (FXR): a novel regulative factor involved in metabolism. Sheng Li Ke Xue Jin Zhan 38: 219-223 (2007).

• Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 103: 1006-1011 (2006). *

• Zhao A, Yu J, Lew JL, Huang L, Wright SD, Cui J. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell. Biol. 23: 519-526 (2004). *

• Zimber A, Gespach C. Bile acids and derivatives, their nuclear receptors FXR, PXR and ligands: role in health and disease and their therapeutic potential. Anticancer Agents Med. Chem. 8: 540-563 (2008).

• Zimmerman TL, Thevananther S, Ghose R, Burns AR, Karpen SJ. Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. J. Biol. Chem. 281: 15434-15440 (2006). *

• Zimniak P, Holsztynska EJ, Lester R, Waxman DJ, Radominska A. Detoxification of lithocholic acid. Elucidation of the pathways of oxidative metabolism in rat liver microsomes. J. Lipid Res. 30: 907-918 (1989). *

• Zinchuk V, Zinchuk O, Akimaru K, Moriya F, Okada T. Ethanol consumption alters expression and colocalization of bile salt export pump and multidrug resistance protein 2 in the rat. Histochem. Cell Biol. 127: 503-512 (2007). *

• Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br. J. Pharmacol. 156: 7-27 (2009). *

• Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int. 27: 920-929 (2007). *

• Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter alpha/beta in the adaptive response to bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G923-G932 (2006). *

• Zou SL, Liu J, Lan Y, Cheng H, Gan XL. Effects of farnesoid X receptor ligand on the metabolism of bile acids in rats with estrogen-induced intrahepatic cholestasis of pregnancy. Zhonghua Gan Zang Bing Za Zhi 16: 383-386 (2008).

Number of references = 708

www psc-literature.org